Heterocyclic il-17a / f compound, preparation method therefor and use thereof
By preparing heterocyclic IL-17A/F small molecule inhibitors, the problem of the lack of effective oral IL-17A inhibitors in the existing technology has been solved, and therapeutic effects on inflammatory diseases such as moderate to severe psoriasis have been achieved.
Patent Information
- Application Number
- PCT/CN2026/097566
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-11-07
- Filing Date
- 2026-05-18
- Publication Date
- 2026-11-19
AI Technical Summary
Currently, there is a lack of effective oral IL-17A inhibitors for the treatment of inflammatory diseases such as moderate to severe psoriasis.
A class of heterocyclic IL-17A/F small molecule inhibitors has been developed. By preparing heterocyclic compounds with specific structures, the production of the cytokine IL-17A/F is inhibited, thereby regulating the inflammatory response.
This compound can effectively inhibit IL-17A/F, reduce inflammatory response, and provide therapeutic effects for diseases such as moderate to severe psoriasis.
Smart Images

Figure CN2026097566_19112026_PF_FP_ABST
Abstract
Description
Heterocyclic IL-17A / F compounds, their preparation methods and applications Technical Field
[0001] This invention belongs to the field of chemical drug technology and relates to a class of heterocyclic IL-17A / F small molecule inhibitors, specifically a heterocyclic IL-17A / F compound and its preparation method and application. Background Technology
[0002] The IL-17 family comprises six cytokines (IL-17A to IL-17F). Interleukin-17A (IL-17A) is a known pro-inflammatory cytokine involved in the induction of IL-6, IL-8, G-CSF, TNF-α, IL-1P, PGE2, and IFN-γ, as well as numerous chemokines and other effectors. IL-17A can form homodimers or heterodimers with its family member IL-17F and can bind to IL-17 receptors IL-17RA and IL-17RC to mediate signal transduction. IL-17A is a major pathological cytokine expressed by Th17 cells, participating in the pathology of inflammation and autoimmune diseases, and also involved in the activity of CD8+ T cells, Y6 cells, NK cells, NKT cells, macrophages, and dendritic cells. IL-17A is a recognized pro-inflammatory cytokine that plays a crucial role in chronic inflammation and is a major driver of tissue damage. IL-17A induces normal immune and inflammatory responses to pathogens, but it can also contribute to chronic autoimmune diseases, including psoriasis, spondyloarthritis, rheumatoid arthritis, and multiple sclerosis.
[0003] Although many patents for small molecule IL-17A inhibitors have been published, such as patent publication numbers WO2020182666, WO2023283453, WO2023275301, and WO2023025783, there are currently no effective oral treatments for moderate to severe psoriasis. Therefore, there is a need to develop effective small molecule IL-17A inhibitors to treat inflammatory diseases and other conditions. Summary of the Invention
[0004] In view of the problems existing in the prior art, this application provides a heterocyclic IL-17A / F inhibitor, its preparation method and application. As an IL-17A / F inhibitor, this compound can inhibit the production of cytokine IL-17A / F, thereby regulating inflammatory responses and related diseases.
[0005] Specifically, the present invention is achieved through the following technical solutions:
[0006] In a first aspect, the present invention provides a compound of formula (I) or a racemic mixture thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof.
[0007] Where a and b are individually selected from 0 or 1, m is selected from 0, 1, 2, 3 or 4, and Y is selected from CH, N, O, and S. When Y is selected from O or S, R 1 It does not exist; Z is selected from C, CH, and N;
[0008] Ring A is selected from at least one R A Substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R A Selected from hydrogen, alkyl, halogen, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, haloalkenyl, halocycloalkyl, -O-cycloalkyl;
[0009] X 1 X 2 Selected independently from hydrogen, Or, X 1 X 2 Together they cyclize into substituted or unsubstituted heterocyclic alkyl or heteroaryl groups, wherein the substituted substituents are selected from alkyl groups and halogens;
[0010] R X1 R X2 It is selected alone from alkyl, alkenyl, alkynyl, nitrile, alkylnitrile, halogen, haloalkyl, haloalkenyl, NT1T2, or substituted or unsubstituted -(CH2). c -N T1T2, -alkyl-O-alkyl, -alkyl-O-cycloalkyl, -alkyl-NH-aryl, -alkyl-NH-heteroaryl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH2) f -cycloalkyl, -(CH2) e -O-alkyl, -(CH2) p -O-cycloalkyl, alkyl heterocyclic alkyl, halocyclic heterocyclic alkyl, -CT3T4-O-alkyl, saturated or unsaturated C 5-12 Ring, C 5-12 Heterocyclic, wherein the substitution is selected from alkyl, cycloalkyl, alkoxy, halogen, haloalkyl, wherein T1, T2, T3, T4 are individually selected from hydrogen, halogen, nitrile, alkyl, haloalkyl, alkoxy, cycloalkyl, heterocyclic alkyl, or T1 and T2, T3 and T4 are cyclized together to substituted or unsubstituted cycloalkyl, heterocyclic alkyl, wherein the substitution is selected from alkyl, halogen, alkoxy, wherein c, f, e, p are selected from 1, 2, 3, 4, 5 or 6;
[0011] R 1 Selected from hydrogen, alkyl, alkoxy, halogen, and haloalkyl;
[0012] R 2 Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2bThe substituent is selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkenyl groups, and the R group is selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkenyl groups. 2a and R 2b Independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups;
[0013] R 3 Selected from hydrogen, halogen, alkyl, and alkoxy groups;
[0014] R 4a R 4b Selected alone from hydrogen, alkyl, halogen, nitrile, alkoxy, haloalkyl, cycloalkyl, or, R 4a R 4b Together they are cyclically converted into at least one R k Substituted cycloalkyl or heterocycloalkyl, wherein the substitution is selected from hydrogen, alkyl, halogen, haloalkyl, or alkoxy;
[0015] R 5 and R 6 It is selected independently from alkyl, alkoxy, cycloalkyl, -AEEA-AEEA-γE-CO-(CH2) t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, wherein the substituent is selected from hydrogen, alkyl, halogen, haloalkyl, -NH2;
[0016] Or, R 5 and R 6 Together they are cyclically converted into at least one R a Substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R a Selected from hydrogen, alkyl, alkoxy, nitrile, alkylnitrile, halogen, cycloalkyl, alkylsulfonyl, alkoxycarbonyl, alkylamino, -alkyl-O-alkyl, haloalkyl, haloalkenyl, -AEEA-AEEA-γE-CO-(CH2) t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, wherein the substituent is selected from hydrogen, alkyl, halogen, haloalkyl, -NH2, and the substitution is at least one, wherein u and v are individually selected from 1, 2, 3, 4, 5 or 6, and t is selected from positive integers from 8 to 20;
[0017] Or R 5 and R 6 Together they become a ring m1, m2, and m3 are each selected from 0, 1, or 2. W is selected from N, CH, O, and S. When W is selected from O or S, R... 9 It does not exist, R 7 and R 8Selected independently from hydrogen, alkyl, haloalkyl, or R 7 and R 8 Together they cyclize into substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups, wherein the substitution is selected from alkyl, alkoxy, halogen, haloalkyl, or cycloalkyl groups, and at least one substitution is performed.
[0018] R 9 Selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, and cycloalkyl.
[0019] As a preferred embodiment of the present invention, the compound, its racemate, its isomer, or its pharmaceutically acceptable salt is selected from the structure shown in formula (Ia). Among them, a, b, m, ring A, and X 1 X 2 Y, R 1 R 2 R 3 R 4a R 4b R 5 R 6 As defined above.
[0020] As a preferred technical solution of the present invention, when a is 0, b is 1, X 2 For hydrogen, R 5 and R 6 Together they become a ring When Z is selected from N, it is selected from the structure shown in equation (II).
[0021] Among them, m1, m2, and m3 are individually selected from 0, 1, or 2;
[0022] m can be 0, 1, 2, 3, or 4;
[0023] W is selected from O, N, and S. When W is selected from O and S, R 9 It does not exist;
[0024] Ring A is selected from at least one R A Substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R A Selected from alkyl, halogen, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, -O-cycloalkyl;
[0025] R 2 Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2b The substituent is selected from alkyl groups and halogens, and the R group is selected from alkyl groups and halogens. 2a and R 2b Independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups;
[0026] R 3 Selected from hydrogen, halogens, and alkyl groups;
[0027] R 4a R 4b Selected alone from alkyl, halogen, nitrile, alkoxy, haloalkyl, cycloalkyl, or, R 4a R 4b Together they cyclize into substituted or unsubstituted cycloalkyl or heterocycloalkyl groups, wherein the substitution is selected from alkyl, halogen, haloalkyl, or alkoxy groups;
[0028] X 1 Selected from
[0029] R X1 R X2 It is selected alone from alkyl, alkenyl, alkynyl, nitrile, alkylnitrile, haloalkyl, haloalkenyl, NT1T2, or substituted or unsubstituted -(CH2). c -N T1T2, or substituted or unsubstituted -(CH2). f -cycloalkyl, -(CH2) e -O-alkyl, alkylheteroalkyl, haloheteroalkyl, or substituted or unsubstituted aryl, heteroaryl, or substituted or unsubstituted cycloalkyl, heteroalkyl, wherein the substitution is selected from alkyl, cycloalkyl, alkoxy, halogen, wherein T1 and T2 are individually selected from alkyl, haloalkyl, cycloalkyl, heteroalkyl, or T1 and T2 together cyclized into substituted or unsubstituted heteroalkyl, wherein the substitution is selected from alkyl, halogen, wherein c, f, e are selected from 1, 2, 3, 4, 5 or 6;
[0030] R 7 and R 8 Selected independently from hydrogen, alkyl, or R 7 and R 8 Together they cyclize into substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups, wherein the substitution is selected from alkyl, alkoxy, halogen, haloalkyl, or cycloalkyl groups, and at least one substitution is performed.
[0031] R 9 Selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, and cycloalkyl;
[0032] Where m1, m2 are 0, m3 is 2, W is N, and R is... 9 For hydrogen, R 7 and R 8 When they cyclize together to form cyclopropyl or cyclobutyl, R 2 Not for
[0033] When ring A is selected from R AReplacement m1 and m2 are 0, m3 is 2, W is N, R 9 When it is methyl, R 7 and R 8 One of them is not hydrogen.
[0034] As a preferred embodiment of the present invention, the compound, or its racemate, its isomer, or its pharmaceutically acceptable salt, is selected from the compound represented by formula (IIa), or its racemate, its isomer, or its pharmaceutically acceptable salt:
[0035] Where m is 1, R 2 Selected from cyclohexyl, cycloheptyl, m1, m2, m3, ring A, X 1 R 2 R 3 R 4a R 4b R 7 R 8 R 9 As defined above.
[0036] As a preferred embodiment of the present invention, when b is 1, X 2 R 4b For hydrogen, R 5 and R 6 Together they become a ring When Z is selected from N, it is selected from the structure shown in equation (III).
[0037] Where m1, m2, and m3 are individually selected from 0, 1, or 2; m is selected from 0, 1, 2, 3, or 4; and a is selected from 0 or 1.
[0038] Y is selected from CH, N, O, and S. When Y is selected from O and S, R 1 It does not exist;
[0039] W is selected from O, N, and S. When W is selected from O and S, R 9 It does not exist;
[0040] Ring A is selected from at least one R A Substituted cycloalkyl, heterocycloalkyl, said R A Selected from alkyl, alkoxy, halogen, and haloalkyl;
[0041] R 1 Selected from hydrogen, alkyl, alkoxy, halogen, and haloalkyl;
[0042] R 2Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2b The substituent is selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkenyl groups, and the R group is selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkenyl groups. 2a and R 2b Independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups;
[0043] R 3 Selected from hydrogen, halogen, alkyl, and alkoxy groups;
[0044] R 4a Selected from hydrogen, halogen, alkyl, alkoxy, and cycloalkyl;
[0045] X 1 Selected from
[0046] R X1 R X2 It is selected alone from alkyl, alkenyl, alkynyl, nitrile, alkylnitrile, halogen, haloalkyl, haloalkenyl, NT1T2, or substituted or unsubstituted -(CH2). c -N T1T2, or substituted or unsubstituted -(CH2). f -cycloalkyl, -(CH2) e -O-alkyl, -(CH2) p -O-cycloalkyl, -CT3T4-O-alkyl, or substituted or unsubstituted aryl, heteroaryl, or substituted or unsubstituted cycloalkyl, heterocycloalkyl, wherein the substitution is selected from alkyl, cycloalkyl, alkoxy, halogen, wherein T1, T2, T3, T4 are individually selected from hydrogen, halogen, nitrile, alkyl, haloalkyl, alkoxy, cycloalkyl, heterocycloalkyl, or T3 and T4 together cyclized into substituted or unsubstituted cycloalkyl, heterocycloalkyl, wherein the substitution is selected from alkyl, halogen, alkoxy, wherein c, f, e, p are selected from 1, 2, 3, 4, 5 or 6;
[0047] R 7 and R 8 Selected independently from hydrogen, alkyl, haloalkyl, or R 7 and R 8 Together they cyclize into substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups, wherein the substitution is selected from alkyl, alkoxy, halogen, haloalkyl, or cycloalkyl groups, and at least one substitution is performed.
[0048] R 9 Selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, and cycloalkyl;
[0049] When Y is selected from O, ring A is selected from cyclopropyl or R 2 Selected from R 3 Selected from fluorine, R 4a Selected from methyl, X 1 Selected from R X1 Selected from ethyl, hour, Selected from
[0050] As a preferred technical solution of the present invention Selected from Further selection R 9 As defined above.
[0051] As a preferred embodiment of the present invention, when a is 1, Y is 0, m1 and m2 are 0, m3 is 1, R 4a When the methyl group is present, the compound, its racemate, its isomer, or its pharmaceutically acceptable salt is selected from the structure shown in formula (IIIa).
[0052] Among them, m, A, W, X 1 R 2 R 3 R 7 R 8 R 9 As defined above.
[0053] As a preferred embodiment of the present invention, the compound, or its racemate, isomer, or pharmaceutically acceptable salt thereof, is selected from the structure shown in formula (IIIb).
[0054] Where m is 1 and R 2 Selected from cycloheptayl, a, m1, m2, m3, A, W, Y, X 1 R 1 R 2 R 3 R 4a R 7 R 8 R 9 As defined above.
[0055] As a preferred technical solution of the present invention, when a is 0, b is 1, X 1 for X 2 When Z is hydrogen and is selected from N, it is selected from the structure shown in formula (IV).
[0056] Where m is 0, 1, 2, 3 or 4;
[0057] Ring A is selected from at least one R A Substituted aryl and heteroaryl, said R A Selected from alkyl, halogen, alkoxy, cycloalkyl, haloalkyl, and haloalkoxy groups;
[0058] R 2 Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2b The substituent is selected from alkyl, halogen, haloalkyl, and haloalkenyl groups, and the R group is selected from alkyl, halogen, haloalkyl, and haloalkenyl groups. 2a and R 2b Independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups;
[0059] R 3 Selected from hydrogen, halogens, and alkyl groups;
[0060] R 4a Selected from hydrogen, halogen, alkyl, cycloalkyl, and alkoxy groups;
[0061] R X1 It is selected alone from alkyl, alkenyl, alkynyl, nitrile, haloalkyl, haloalkenyl, or substituted or unsubstituted -(CH2). e -O-alkyl, -(CH2) p -O-cycloalkyl, saturated or unsaturated C 5-12 Ring, C 5-12 Heterocyclic, wherein the substitution is selected from alkyl, halogen, alkoxy, or haloalkyl;
[0062] R 5 and R 6 Selected alone from alkyl, alkoxy, cycloalkyl; or, R 5 and R 6 Together they cyclize into substituted or unsubstituted heterocyclic alkyl groups, wherein the substitution is selected from alkyl, alkoxy, nitrile, alkyl nitrile, halogen, cycloalkyl, alkylsulfonyl, alkoxycarbonyl, alkylamino, -(CH2). e -O-alkyl, haloalkyl, haloalkenyl, wherein the substitution is at least one, and e and p are selected from 1, 2, 3, 4, 5 or 6.
[0063] As a preferred technical solution of the present invention, the saturated or unsaturated C 5-12 Metacycles are selected from: The saturated or unsaturated C 5-12 Metacycles are selected from:
[0064] As a preferred technical solution of the present invention, when R 4a Methyl, m = 1, R 3 When the compound is fluorine, the compound, or its racemate, isomer, or pharmaceutically acceptable salt thereof, is selected from the structure shown in formula (IVa). Among them, R 2 Selected from Ring A, R X1 R 5 R 6 As stated above.
[0065] As a preferred technical solution of the present invention, when a is 0, b is 1, and R... 4b When hydrogen is used, the structure is selected from that shown in formula (V).
[0066] Where m is 0, 1, 2, 3 or 4; Z is selected from C, CH, N;
[0067] Ring A is selected from at least one R A Substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R A Selected from alkyl, halogen, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, -O-cycloalkyl;
[0068] R 2 Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2b ), the R 2a and R 2b The substituents are independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and the substituted substituents are selected from alkyl, halogen, haloalkyl, and haloalkenyl.
[0069] R 3 Selected from hydrogen, halogens, and alkyl groups;
[0070] R 4a Selected from hydrogen, halogens, alkyl groups, and cycloalkyl groups;
[0071] X 1 X 2 Selected independently from hydrogen, Or, X 1 X 2 Together they cyclize into substituted or unsubstituted heterocyclic alkyl or heteroaryl groups, wherein the substituted substituents are selected from alkyl groups and halogens;
[0072] R X1 R X2The substituent is selected from alkyl, alkenyl, alkynyl, nitrile, alkylnitrile, haloalkyl, haloalkenyl, or substituted or unsubstituted -alkyl-O-alkyl, -alkyl-O-cycloalkyl, -alkyl-NH-aryl, -alkyl-NH-heteroaryl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein the substituted substituent is selected from alkyl, halogen, alkoxy, haloalkyl;
[0073] R 5 and R 6 It is selected independently from alkyl, alkoxy, cycloalkyl, -AEEA-AEEA-γE-CO-(CH2) t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, R 5 and R 6 At least one of them is selected from -AEEA-AEEA-γE-CO-(CH2). t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, wherein the substituent is selected from hydrogen, alkyl, halogen, haloalkyl, -NH2;
[0074] Or, R 5 and R 6 Together they are cyclically formed by at least one R a Substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R a Selected from hydrogen, alkyl, alkoxy, halogen, cycloalkyl, -alkyl-O-alkyl, haloalkyl, -AEEA-AEEA-γE-CO-(CH2) t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, and at least one R a Selected from -AEEA-AEEA-γE-CO-(CH2) t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, wherein the substituent is selected from hydrogen, alkyl, halogen, haloalkyl, -NH2, wherein u and v are individually selected from 1, 2, 3, 4, 5 or 6, and t is selected from positive integers from 8 to 20.
[0075] As a preferred embodiment of the present invention, -AEEA-AEEA-γE-CO-(CH2) t The structure of -CO2H is:
[0076] t is selected from 10, 12, 14, 16, 18, and 20, with 16 and 18 being preferred.
[0077] When t is 16, the structure is:
[0078] When t is 18, the structure is:
[0079] As a preferred technical solution of the present invention, the structure is selected from the one shown in formula (Va).
[0080] Wherein, d is selected from 1, 2, 3, 4, 5, T is selected from CH2, NH, A ring, R 2 R 3 R 4a R a X 1 X 2 m is as defined above.
[0081] As a preferred technical solution of the present invention, the structure is selected from the one shown in formula (Va').
[0082] Wherein, d is selected from 1, 2, 3, 4, 5, T is selected from CH2, NH, A ring, R 2 R 3 R 4a R a X 1 X 2 m is as defined above.
[0083] As a preferred technical solution of the present invention, the structure is selected from the structure shown in formula (Vb) and (Vb').
[0084] Among them, R a1 R a2 R at different substitution sites a Furthermore, R a1 Selected alone from -AEEA-AEEA-γE-CO-(CH2) t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, wherein the substituent is selected from hydrogen, alkyl, halogen, haloalkyl, -NH2; R a2 Selected independently from hydrogen, alkyl, alkoxy, halogen, cycloalkyl, -alkyl-O-alkyl, haloalkyl, A ring, R 2 R 3 R 4a X 1 X 2m is as defined above.
[0085] As a preferred embodiment of the present invention, when a is 0, b is 0, and Z is CH, the structure shown in formula (VI) is selected.
[0086] Where m and n are each selected from 0, 1, 2, 3 or 4;
[0087] Ring A is selected from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups;
[0088] R A Selected from alkyl, halogen, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, -O-cycloalkyl;
[0089] R 2 Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2b ), the R 2a and R 2b The substituents are independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and the substituted substituents are selected from alkyl, halogen, haloalkyl, and haloalkenyl.
[0090] R 3 Selected from hydrogen, halogens, and alkyl groups;
[0091] R 4a R 4b Selected independently from hydrogen, halogen, alkyl, alkoxy, cycloalkyl, or R 4a R 4b Together they are cyclically converted into at least one R k Substituted cycloalkyl, heterocycloalkyl, said R k Selected from hydrogen, alkyl, halogen, and haloalkyl;
[0092] X 1 X 2 Selected independently from hydrogen, Or, X 1 X 2 Together they cyclize into substituted or unsubstituted heterocyclic alkyl or heteroaryl groups, wherein the substituted substituents are selected from alkyl groups and halogens;
[0093] R X1 R X2 The substituent is selected from alkyl, alkenyl, alkynyl, nitrile, alkylnitrile, haloalkyl, haloalkenyl, or substituted or unsubstituted -alkyl-O-alkyl, -alkyl-O-cycloalkyl, -alkyl-NH-aryl, -alkyl-NH-heteroaryl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein the substituted substituent is selected from alkyl, halogen, alkoxy, haloalkyl;
[0094] R 5 and R 6 Together they are cyclically formed by at least one R a Substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R a The substituents are selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl, substituted cycloalkyl, substituted -alkyl-O-alkyl, substituted -alkyl-O-cycloalkyl, wherein the substituents are selected from hydrogen, alkyl, halogen, haloalkyl;
[0095] Where, when m is 0 or 1, R 4a R 4b Neither of them are hydrogen, or R 4a R 4b Together they are cyclically converted into at least one R k Substituted cycloalkyl and heterocycloalkyl groups.
[0096] As a preferred technical solution of the present invention, the structure shown in formula (VI') is selected. Among them, ring A and ring R A R 2 R 3 R 4a R 4b R 5 R 6 X 1 X 2 m and n are defined as above.
[0097] As a preferred technical solution of the present invention, the structure is selected from the structure shown in formulas (VIa) and (VIa').
[0098] Among them, R 4a R 4b Neither of them are hydrogen, or R 4a R 4b Together they are cyclically converted into at least one R k Substituted cycloalkyl, heterocycloalkyl, A ring, R ring A R 2 R 3 R 4a R 4b R 5 R 6 X 1 X 2 n is as defined above.
[0099] As a preferred embodiment of the present invention, when m is 2, the structures selected from formulas (VIb) and (VIb') are selected from the structures shown.
[0100] Among them, R 3a R 3b R at different substitution sites 3 R 3a R 3b Selected independently from alkyl groups, halogens, A rings, and R rings. A R 2 R 4a R 4b R 5 R 6 X 1 X 2 n is as defined above.
[0101] As a preferred technical solution of the present invention, the structure is selected from one of the formulas (VIc) and (VIc').
[0102] Where k is 1, 2, 3, 4, 5 or 6, A ring, R 2 R 3 R 5 R 6 R k X 1 X 2 m and n are defined as above.
[0103] As a preferred embodiment of the present invention, the compound, or its racemate, isomer, or pharmaceutically acceptable salt thereof, is selected from the structures represented by formulas (VId), (VIe), (VIf), (VId'), (VIe'), and (VIf'). Among them, ring A and ring R 2 R 3 R 3a R 3b R 4a R 4b R a R k R A X 1 X 2 m and n are defined as above.
[0104] As a preferred embodiment of the present invention, the alkyl group is selected from C. 1-6 alkyl group, the C 1-6The alkyl group is selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, 1-ethylpropyl, 2-methylbutyl, tert-pentyl, 1,2-dimethylpropyl, isopentyl, neopentyl, n-hexyl, isohexyl, sec-hexyl, tert-hexyl, neohexyl, 2-methylpentyl, 1,2-dimethylbutyl, and 1-ethylbutyl.
[0105] The alkoxy group is selected from C. 1-6 The alkoxy group, the C 1-6 The alkoxy group is selected from methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, sec-pentoxy, 1-ethylpropoxy, 2-methylbutoxy, tert-pentoxy, 1,2-dimethylpropoxy, isopentoxy, neopentoxy, n-hexyloxy, isohexyloxy, sec-hexyloxy, tert-hexyloxy, neohexyloxy, 2-methylpentoxy, 1,2-dimethylbutoxy, and 1-ethylbutoxy; the aryl group is selected from five-membered or six-membered aryl groups; the heteroaryl group refers to an aryl group in which at least one carbon atom is substituted by a heteroatom;
[0106] The alkenyl group is selected from C. 2-6 alkenyl, C 2-6The alkenyl group is selected from vinyl, 1-propenyl, 2-propenyl, 1-methylvinyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl 3-Methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl 2-Methyl-3-pentenyl, 3-Methyl-3-pentenyl, 4-Methyl-3-pentenyl, 1-Methyl-4-pentenyl, 2-Methyl-4-pentenyl, 3-Methyl-4-pentenyl, 4-Methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-1-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl alkenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-1-butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl and 1-ethyl-2-methyl-2-propenyl;
[0107] The alkynyl group is selected from C. 2-6 The alkynyl group, the C 2-6 The alkynyl group is selected from ethynyl, propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 2-hexynyl, and 3-hexynyl.
[0108] The alkyl nitrile is selected from acetonitrile, propionitrile, butyronitrile, isobutyronitrile, valerate, isovaleritrile, and hexanonitrile;
[0109] The aryl group is selected from five-membered or six-membered aryl groups; the heteroaryl group refers to an aryl group in which at least one carbon atom is substituted by a heteroatom, and further, the heteroaryl group is selected from five-membered or six-membered heteroaryl groups. Preferred
[0110] As a preferred embodiment of the present invention, the cycloalkyl group is selected from C 3-12 Cycloalkyl groups, preferably the C 3-12 The cycloalkyl group is selected from C 3-8 cycloalkyl, C 3-8 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclic alkyl, bridged cycloalkyl, and spirocyclic alkyl; the heterocyclic alkyl group refers to a cycloalkyl group in which at least one carbon atom is replaced by a heteroatom; the alkyl heterocyclic alkyl group refers to a heterocyclic alkyl group in which at least one hydrogen atom is replaced by an alkyl group; the spirocyclic alkyl group refers to a cycloalkyl group in which two cycloalkyl groups share one carbon atom; and the bicyclic alkyl group refers to a cycloalkyl group in which two cycloalkyl groups share two carbon atoms.
[0111] As a preferred embodiment of the present invention, the spirocycloalkyl group is selected from...
[0112] As a preferred embodiment of the present invention, the halogen is selected from fluorine, chlorine, bromine, and iodine; a haloalkyl means that at least one hydrogen atom on an alkyl group is replaced by a halogen, and a haloheteroalkyl means that at least one hydrogen atom on a heterocyclic alkyl group is replaced by a halogen.
[0113] As a preferred embodiment of the present invention, the heteroatom is selected from nitrogen, oxygen, and sulfur, and there are one or more heteroatoms.
[0114] Specifically, the heterocyclic alkyl group is selected from...
[0115] In a preferred embodiment of the present invention, a is 0 or 1, b is 0 or 1; m is 1 or 2; Y is O or N; Z is CH or N;
[0116] Ring A is selected from cyclopropyl, cyclobutyl, ... By at least one R A The replaced A ring is selected from
[0117] and / or R 1 Selected from hydrogen and methyl;
[0118] and / or R 2 Selected from cyclohexyl, cycloheptyl,
[0119] and / or R 3 Selected from fluorine;
[0120] and / or R 4a R 4b Selected independently from hydrogen, methyl, or R 4a R 4b They cyclize together to form cyclopropyl and cyclobutyl groups;
[0121] and / or X 1 X 2 Selected independently from hydrogen,
[0122] R X1 Selected from ethyl,
[0123] and / or R 5 and R 6 Together they formed a ring Further selection R 9 As defined above.
[0124] In a preferred embodiment of the present invention, m1 and m2 are 0, m3 is 2, m is 1, and W is N;
[0125] The A ring is selected from: The at least one R A The replaced A ring is selected from
[0126] R 2 Selected from cyclohexyl, cycloheptyl,
[0127] R 3 Selected from fluorine;
[0128] R 4a R 4b They cyclize together to form cyclopropyl and cyclobutyl groups;
[0129] X 1 Selected from
[0130] R X1 Selected from ethyl,
[0131] R 7 Selected from hydrogen, R 8 Selected from methyl, or R 7 and R 8They cyclize together to form cyclopropyl and cyclobutyl groups;
[0132] R 9 It consists of hydrogen and methyl groups.
[0133] In a preferred embodiment of the present invention, m1 and m2 are selected from 0, m3 is selected from 2; m is selected from 1; Y is selected from N and O, and W is selected from N;
[0134] A is selected from cyclopropyl, cyclobutyl,
[0135] R 1 Selected from hydrogen and methyl;
[0136] R 2 Selected from cycloheptayl,
[0137] R 3 Selected from fluorine;
[0138] R 4a Selected from methyl;
[0139] Z is selected from R X1 Selected from ethyl,
[0140] R 5 Selected alone from hydrogen, R 6 Selected from methyl, Or, R 5 and R 6 They cyclize together to form a cyclopropyl group.
[0141] In a preferred embodiment of the present invention, m is 1; the A ring is selected from... The at least one R A The replaced A ring is selected from R 2 Selected from R 3 Selected from fluorine; R 4a Selected from methyl;
[0142] R X1 Selected from ethyl,
[0143] R 5 and R 6 Together they formed a ring
[0144] In a preferred embodiment of the present invention, m is 1;
[0145] and / or t is 16;
[0146] And / or Z is N;
[0147] And / or ring A is selected from By at least one R A The replaced A ring is selected from:
[0148] and / or R 2 Selected from cycloheptayl,
[0149] and / or R 3 Selected from fluorine;
[0150] and / or R 4a Selected from methyl;
[0151] and / or X 1 Selected from X 2 Selected from hydrogen, R X1 Selected from ethyl,
[0152] and / or R 5 and R 6 Together they form a ring:
[0153] In a preferred embodiment of the present invention, m is 1 or 2; and / or n is 1;
[0154] And / or ring A is selected from By at least one R A The replaced A ring is selected from:
[0155] and / or R 2 Selected from
[0156] and / or R 3 Selected from fluorine;
[0157] and / or R 4a R 4b Selected independently from hydrogen, methyl, or R 4a R 4b They cyclize together to form a cyclopropyl group;
[0158] and / or X 1 Selected from X 2 Selected from hydrogen, the R X1 Selected from ethyl,
[0159] and / or R 5 R 6 Together they become a ring
[0160] As a preferred embodiment of the present invention, the pharmaceutically acceptable salt refers to a compound, or its isomer, or its racemate, or its pharmaceutically acceptable salt, prepared with a pharmaceutically acceptable acid or base.
[0161] As a preferred embodiment of the present invention, one or more hydrogen atoms of the compound, or its isomer, racemate, or pharmaceutically usable salt thereof, are replaced by the isotope deuterium.
[0162] In a second aspect, the present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of any of the preceding compounds, or a racemic mixture thereof, an isomer thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier thereof.
[0163] Thirdly, the present invention also provides the use of the compound, or a racemic mixture thereof, or an isomer thereof, or a pharmaceutically usable salt thereof, and the pharmaceutical composition described above, in the preparation of a medicament for treating a disease, said disease being an IL-17A / F-related disease, specifically selected from diseases such as psoriasis and arthritis.
[0164] For clarity, this article defines the general terminology used in the description of compounds.
[0165] Unless otherwise stated, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be considered uncertain or unclear unless specifically defined, but should be understood in its ordinary sense. When a trade name appears herein, it is intended to refer to the corresponding product or its active ingredient. The term "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without undue toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.
[0166] The term "medicinal salt" refers to a salt of the compounds of the present invention, prepared from a compound having specific substituents as discovered in the present invention with a pharmaceutically acceptable acid or base.
[0167] In addition to the salt form, the compounds provided by this invention also exist in prodrug form. The prodrugs of the compounds described herein readily undergo chemical changes under physiological conditions to be converted into the compounds of this invention. Furthermore, the prodrugs can be converted into the compounds of this invention in the in vivo environment via chemical or biochemical methods.
[0168] Some compounds of this invention may exist in non-solventized or solvated forms, including hydrated forms. Generally, solvated and non-solventized forms are equivalent and both are included within the scope of this invention.
[0169] The compounds of this invention can exist in specific geometric or stereoisomeric forms. This invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)- enantiomers, (R)- and (S)- enantiomers, diastereomers, (D)- isomers, (L)- isomers, transisomers, racemic mixtures thereof, and other mixtures, such as mixtures enriched with enantiomers or diastereomers, all of which are within the scope of this invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are included within the scope of this invention.
[0170] Optically active (R)- and (S)- isomers, as well as D- and L- isomers, transisomers, etc., can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. To obtain an enantiomer of a compound of the present invention, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated, and the auxiliary group is cleaved to provide the desired enantiomer in pure form. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a salt of the diastereomeric isomer is formed with a suitable optically active acid or base, followed by diastereomeric resolution using conventional methods known in the art, and then the pure enantiomer is recovered. Furthermore, the separation of enantiomers and diastereomeric isomers is typically accomplished by using chromatography employing a chiral stationary phase and optionally combined with chemical derivatization (e.g., from amines to carbamates).
[0171] The atoms in the compounds of this invention are isotopes. Isotope derivatization can typically prolong half-life, reduce clearance rate, stabilize metabolism, and enhance in vivo activity. Furthermore, one embodiment is included, wherein at least one atom is replaced by an atom having the same number of atoms (protons) but different mass numbers (protons and neutrons). Examples of isotopes included in the compounds of this invention include hydrogen atoms, carbon atoms, nitrogen atoms, oxygen atoms, phosphorus atoms, sulfur atoms, fluorine atoms, and chlorine atoms, each comprising... 2 H, 3 H, 13 C 14 C 15 N、 17 O、 18 O、 31 P, 32 P, 35 S, 18 F, 36 Cl. In particular, radioactive isotopes that emit radiation as they decay, such as 3 H or 14C can be used for local anatomical examination of pharmaceutical preparations or compounds in vivo. Stable isotopes neither decay nor change with quantity and are not radioactive, therefore they can be used safely. When the atoms constituting the compounds of this invention are isotopes, the isotopes can be converted according to common methods by replacing the reagents used in the synthesis with reagents containing the corresponding isotopes.
[0172] The compounds of this invention may contain atomic isotopes in non-natural proportions on one or more atoms constituting the compound. For example, the compounds may be labeled with radioactive isotopes, such as deuterium. 2 H), Iodine-125 125 I) or C-14 14 C). All isotopic variations of the compounds of the present invention, regardless of radioactivity, are included within the scope of the present invention.
[0173] Furthermore, one or more hydrogen atoms in the compound of the present invention are coated with the isotope deuterium ( 2 The compounds of this invention, after being substituted with H), have the effects of prolonged half-life, reduced clearance rate, metabolic stabilization, and increased in vivo activity.
[0174] The preparation methods of the isotope derivatives typically include phase-transfer catalysis. For example, a preferred deuteration method employs a phase-transfer catalyst (e.g., tetraalkylammonium salt, NBu4HSO4). Using a phase-transfer catalyst to exchange the methylene protons of a diphenylmethane compound results in the introduction of higher levels of deuterium than reduction with deuterated silanes (e.g., triethyldeuterated silane) in the presence of an acid (e.g., methanesulfonic acid) or with Lewis acids such as aluminum trichloride using sodium deuterated borate.
[0175] The term "pharmaceutically acceptable carrier" refers to any formulation carrier or medium capable of delivering an effective amount of the active substance of this invention without interfering with the biological activity of the active substance and without toxic side effects on the host or patient. Representative carriers include water, oil, vegetables and minerals, ointment bases, lotion bases, and ointment bases. These bases include suspending agents, thickeners, and transdermal penetration enhancers. Their formulations are well known to those skilled in the art of cosmetics or topical pharmaceuticals. For further information on carriers, see Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005), the contents of which are incorporated herein by reference.
[0176] The term "excipient" generally refers to the carrier, diluent, and / or medium required to formulate an effective pharmaceutical composition.
[0177] For pharmaceuticals or pharmacologically active agents, the term "effective amount" or "therapeutic effective amount" refers to a sufficient quantity of a drug or agent that is non-toxic but achieves the desired effect. For the oral dosage forms of this invention, the "effective amount" of one active substance in the composition refers to the quantity required to achieve the desired effect when used in combination with another active substance in the composition. The determination of the effective amount varies from person to person, depending on the recipient's age and general condition, as well as the specific active substance. A suitable effective amount in any given case can be determined by a person skilled in the art through routine testing.
[0178] The terms “active ingredient,” “therapeutic agent,” “active substance,” or “active agent” refer to a chemical entity that can effectively treat a target disorder, disease, or symptom.
[0179] "Optional" or "optionally" means that the event or condition described below may occur but is not required to occur, and the description includes both the scenario in which said event or condition occurs and the scenario in which said event or condition does not occur.
[0180] Indicates a connection key.
[0181] The compounds of the present invention can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthetic methods, and equivalent substitutions known to those skilled in the art. Preferred embodiments include, but are not limited to, the embodiments of the present invention. Detailed Implementation
[0182] The present application will be described in further detail below with reference to the embodiments, but the implementation of the present application is not limited thereto.
[0183] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR shifts (R shifts) are given in units of 10⁻⁶ (ppm). NMR measurements were performed using a Bruker AVANCE-III NMR spectrometer with deuterated dimethyl sulfoxide (DMSO-d₆) and deuterated chloroform (CDCl₃) as the solvents and tetramethylsilane (TMS) as the internal standard. MS measurements were performed using an ISQ EC mass spectrometer (manufacturer: Thermo, model: ISQ EC).
[0184] High-performance liquid chromatography (HPLC) analysis was performed using a Thermo U3000 HPLC DAD system. The CombiFlash rapid preparation system used a CombiFlash Rf+LUMEN (TELEDYNE ISCO) instrument. Thin-layer chromatography (TLC) used Yantai Yinlong HSGF254 or GF254 silica gel plates. The silica gel plates used for TLC had a diameter of 0.17 mm to 0.23 mm, while the plates used for TLC separation and purification had a diameter of 0.4 mm to 0.5 mm. Silica gel column chromatography generally used Rushan Shangbang 100-200 mesh silica gel as the carrier.
[0185] The synthetic route of this invention is as follows:
[0186] Synthesis Route 1:
[0187] Among them, R 2 R 4a R 4b R 9 As defined above, the A ring can be synthesized by referring to the methods described in patent documents CN202080079537.5 and WO2025 / 080986.
[0188] Synthesis Route 2
[0189] Synthesis Route 3
[0190] Among them, R 2 R 4a R 4b As defined above, the A ring can be synthesized by referring to the methods described in patent documents CN202080079537.5 and WO2025 / 080986.
[0191] Synthesis Route 4:
[0192] Synthesis Route 5:
[0193] Synthesis Route 6:
[0194] Among them, R 4 As mentioned above, R 4a As defined, ring A, ring R a R X1 k is as defined above.
[0195] Intermediate 1
[0196] The synthetic route for intermediate 1 can be found in the synthetic route described in patent application CN202380035861.0.
[0197] Intermediate 2
[0198] The synthetic route for intermediate 2 can be found in the synthetic route described in patent application CN202380035861.0.
[0199] Preparation of intermediate 3
[0200] Synthesize (2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazol-5-carbamoyl)propamido)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-ylamino)propamido)butyric acid.
[0201] The synthesis route is as follows:
[0202] Step A: Synthesis of (2R,3S)-2-((S)-2-((tert-butoxycarbonyl)amino)propamido)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)benzyl butyrate
[0203] At room temperature, benzyl (2R,3S)-2-amino-3-[(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)butyrate (720 mg, 1.25 mmol, 1 eq) and (tert-butoxycarbonyl)-L-alanine (189 mg, 1.88 mmol, 1.5 eq) were dissolved in 10 mL of DMF solution. Under nitrogen protection, DIPEA (484.94 mg, 3.75 mmol, 3 eq) and HATU (713 mg, 1.88 mmol, 1.5 eq) were added. The reaction mixture was stirred at 25 °C for 2 hours.
[0204] Post-processing: After the reaction was completed, the reaction solution was extracted with water and EA. The organic phase was collected, dried over anhydrous sodium sulfate, and evaporated to dryness to obtain crude (2R,3S)-2-((S)-2-((tert-butoxycarbonyl)amino)propamido)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)benzyl butyrate (1 g). LC-MS: [M+H] + =747.
[0205] Step B: (2R,3S)-2-((S)-2-aminopropionamido)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propionamido)-3-fluorophenyl)benzyl butyrate
[0206] At room temperature, crude (2R,3S)-2-((S)-2-((tert-butoxycarbonyl)amino)propamido)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)benzyl butyrate (1 g, 1.23 mmol, 1 eq) was added to dichloromethane (10 mL), followed by the addition of TFA (2 mL, 21 eq) and stirred at room temperature for 1.5 hours.
[0207] Post-treatment: After the reaction was complete, the reaction solution was directly evaporated to dryness and dissolved in EA. The solution was then adjusted to weakly alkaline with saturated sodium bicarbonate. The mixture was extracted with EA, and the organic phase was collected, dried over anhydrous sodium sulfate, and evaporated to dryness to obtain crude (2R,3S)-2-((S)-2-aminopropionamido)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propionamido)-3-fluorophenyl)benzyl butyrate (720 mg), which was directly used in the next step. LC-MS: [M+H] + =647.
[0208] Step C: (2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazol-5-carbamoyl)propamido)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-ylamino)propamido)benzyl butyrate
[0209] At room temperature, crude (2R,3S)-2-((S)-2-aminopropamido)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl) benzyl butyrate (720 mg, 1.11 mmol, 1 eq), 2-chloropyrimidine (382 mg, 3.33 mmol, 3 eq) and DIPEA (710 mg, 5.5 mmol, 5 eq) were dissolved in NMP (10 mL), and the reaction solution was then microwaved to 150 °C for 2 hours.
[0210] Post-treatment: After the reaction was completed, the reaction solution was extracted with water and EA. The organic phase was evaporated to dryness through a normal phase (DCM:MeOH = 97:3) to obtain (2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazol-5-carboxamido)propamido)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-ylamino)propamido)benzyl butyrate (530 mg). LC-MS: [M+H] + =725.
[0211] Step D: (2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazol-5-carbamoyl)propamido)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-ylamino)propamido)butyric acid
[0212] At room temperature, benzyl butyrate (2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carbamoyl)propamido)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-ylamino)propamido)butyrate (530 mg, 731 μmol, 1 eq) was dissolved in MeOH (10 mL), followed by the addition of humidified Pd / C (70 mg, 0.1 eq) g, and the reaction was carried out under a hydrogen atmosphere with stirring for 12 hours.
[0213] Post-processing: After the reaction was completed, the reaction solution was filtered through diatomaceous earth, the organic phase was evaporated to dryness, and passed through a reverse-phase filter (H2O / ACN) to obtain intermediate 3 (85 mg). LC-MS: [M+H] + =635.
[0214] Preparation of intermediate 4
[0215] The synthetic route for (2R,3S)-3-[4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carbamoyl)propamido)-3-fluorophenyl]-2-((S)-2-methoxypropamido)butyric acid is as follows:
[0216] Step A: Synthesis of (2R,3S)-2-((tert-butoxycarbonyl)amino)-3-(3-fluoro-4-nitrophenyl)butyrate benzyl ester
[0217] At room temperature, ((2R,3S)-2-((tert-butoxycarbonyl)amino)-3-(3-fluoro-4-nitrophenyl)butyric acid (27.5 g, 7.5 mmol) and sodium bicarbonate (30.3 g, 0.219 mmol) were dissolved in DMF (300 mL), and benzyl bromide (27.5 g, 7.5 mmol) and sodium bicarbonate (30.3 g, 0.219 mmol) were added dropwise at 0 L, and the mixture was stirred overnight at room temperature.
[0218] Post-treatment: Add saturated sodium bicarbonate aqueous solution (500 mL), extract with ethyl acetate (500 mL × L), combine the organic phases, wash with saturated brine (500 mL × L), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate to dryness to give a yellow oily liquid (2R,3S)-2-((tert-butoxycarbonyl)amino)-3-(3-fluoro-4-nitrophenyl)butyrate (63.2 g). LC-MS: [M+H] + =433.
[0219] Step B: Synthesis of (2R,3S)-2-amino-3-(3-fluoro-4-nitrophenyl)butyrate benzyl ester
[0220] At room temperature, (2R,3S)-2-((tert-butoxycarbonyl)amino)-3-(3-fluoro-4-nitrophenyl)butyrate benzyl butyrate (millimol) was dissolved in dichloromethane (150 mL), and trifluoroacetic acid (100 mL, 3 millimol) was added. The mixture was stirred at room temperature for 1 hour.
[0221] Post-treatment: Concentrate the residue, adjust the pH to alkaline with saturated sodium bicarbonate solution, extract with ethyl acetate (500 mL × L), combine the organic phases, wash with saturated brine (500 mL × L), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate to dryness to give a yellow oily liquid (2R,3S)-2-amino-3-(3-fluoro-4-nitrophenyl)butyrate (47.7 g). LC-MS: [M+H] + =333.
[0222] Step C: Synthesis of (2R,3S)-3-(3-fluoro-4-nitrophenyl)-2-((S)-2-methoxypropamido)benzyl butyrate
[0223] At room temperature, (2R,3S)-2-amino-3-(3-fluoro-4-nitrophenyl)butyrate benzyl ester (47.7 g, 143 mmol) was dissolved in DMF (200 mL), and (S)-2-methoxypropionic acid (16.4 g, 158 mmol), DIPEA (75.2 mL, 430.6 mmol), and HATU (82 g, 215 mmol) were added. The mixture was stirred at room temperature for 1 h.
[0224] Post-treatment: Dilute with saturated sodium bicarbonate aqueous solution (500 mL), extract with ethyl acetate (300 mL × L), combine the organic phases, wash with saturated brine (500 mL × L), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate to dryness to give a yellow oily liquid (2R,3S)-3-(3-fluoro-4-nitrophenyl)-2-((S)-2-methoxypropamido)butyrate benzyl ester (60 g). LC-MS: [M+H]+ =419.
[0225] Step D: Synthesis of (2R,3S)-3-(4-amino-3-fluorophenyl)-2-((S)-2-methoxypropamido)benzyl butyrate
[0226] At room temperature, (2R,3S)-3-(3-fluoro-4-nitrophenyl)-2-((S)-2-methoxypropamido)benzyl butyrate (60 g, 0.143 mmol) was dissolved in ethanol (180 mL) and water (90 mL), and iron powder (40 g, 7.17 mmol) and ammonium chloride (38.4 g, 7.17 mmol) were added. The mixture was heated to 80°C and reacted for 1 hour.
[0227] Post-treatment: The mixture was filtered through diatomaceous earth, concentrated, and the residue was added to a saturated sodium bicarbonate aqueous solution (300 mL). Extraction was performed with ethyl acetate (500 mL × L). The organic phases were combined, washed with saturated brine (300 mL × L), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give a yellow oily liquid (2R,3S)-3-(4-amino-3-fluorophenyl)-2-((S)-2-methoxypropamido)butyrate benzyl ester (55.7 g). LC-MS: [M+H] + =389.
[0228] Step E: Synthesis of (2R,3S)-3-(4-(2-((tert-butoxycarbonyl)amino)-3,3-dicyclopropylpropamido)-3-fluorophenyl)-2-((S)-2-methoxypropamido)benzyl butyrate
[0229] At room temperature, (2R,3S)-3-(4-amino-3-fluorophenyl)-2-((S)-2-methoxypropamido)benzyl butyrate (55.7 g, 5143 mmol) was dissolved in pyridine (300 mL), and (2S)-2-{[(tert-butoxy)carbonyl]amino}-3,3-dicyclopropylpropionic acid (46.4 g, 172 mmol) and EDCI (82.5 g, 430 mmol) were added. The mixture was stirred at room temperature for 1 hour.
[0230] Post-treatment: Concentrate the residue, add saturated sodium bicarbonate aqueous solution (500 mL), extract with ethyl acetate (300 mL × 3), combine the organic phases, wash with saturated brine (300 mL × 2), dry the organic phase with anhydrous sodium sulfate, filter, concentrate to dryness, and give a pale yellow solid. Add appropriate amounts of methanol, ethanol, and water, stir overnight, and filter to give (2R,3S)-3-(4-(2-((tert-butoxycarbonyl)amino)-3,3-dicyclopropylpropamido)-3-fluorophenyl)-2-((S)-2-methoxypropamido)benzyl butyrate (88 g). LC-MS: [M+H] + =640.
[0231] Step F: Synthesis of benzyl(2R,3S)-3-[4-((S)-2-amino-3,3-dicyclopropylpropamido)-3-fluorophenyl]-2-((S)-2-methoxypropamido)butyrate
[0232] At room temperature, (2R,3S)-3-(4-(2-((tert-butoxycarbonyl)amino)-3,3-dicyclopropylpropamido)-3-fluorophenyl)-2-((S)-2-methoxypropamido)benzyl butyrate (88 g, 8137 mmol) was dissolved in dichloromethane (100 mL), and trifluoroacetic acid (100 mL, 1320 mmol) was added. The mixture was stirred at room temperature for 1 hour.
[0233] Post-treatment: Concentrate, adjust pH to alkaline by adding saturated sodium bicarbonate aqueous solution to the residue, extract with ethyl acetate (500 mL × L), combine organic phases, wash with saturated brine (300 mL × L), dry the organic phase with anhydrous sodium sulfate, filter, concentrate the filtrate to dryness, and give a yellow oily liquid benzyl(2R,3S)-3-[4-((S)-2-amino-3,3-dicyclopropylpropamido)-3-fluorophenyl]-2-((S)-2-methoxypropamido)butyrate (74 g). LC-MS: [M+H] + =540.
[0234] Step G: Synthesis of benzyl(2R,3S)-3-[4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carbamoyl)propamido)-3-fluorophenyl]-2-((S)-2-methoxypropamido)butyrate
[0235] At room temperature, (2R,3S)-3-[4-((S)-2-amino-3,3-dicyclopropylpropamido)-3-fluorophenyl]-2-((S)-2-methoxypropamido)butyrate (67.7 g, 7125 mmol) was dissolved in N,N-dimethylformamide (200 mL), and 1-ethyl-1H-pyrazole-5-carboxylic acid (21 g, 140 mmol), HATU (72 g, 188 mmol) and DIPEA (88 mL, 501 mmol) were added, and the mixture was stirred at room temperature for 1 hour.
[0236] Post-treatment: Add saturated sodium bicarbonate aqueous solution (500 mL), extract with ethyl acetate (300 mL × 3), combine the organic phases, wash with saturated brine (300 mL × 2), dry the organic phase with anhydrous sodium sulfate, filter, concentrate to dryness, add appropriate amounts of methanol, ethyl acetate and water to the crude product, stir overnight, filter to obtain benzyl(2R,3S)-3-[4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl]-2-((S)-2-methoxypropamido)butyrate (82 g). LC-MS: [M+H] + =662.
[0237] Step H: Synthesis of (2R,3S)-3-[4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carbamoyl)propamido)-3-fluorophenyl]-2-((S)-2-methoxypropamido)butyric acid
[0238] At room temperature, benzyl(2R,3S)-3-[4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl]-2-((S)-2-methoxypropamido)butyrate (82 g, 2124 mmol) was dissolved in methanol (100 mL) and dichloromethane (100 mL), and palladium on carbon (8 g, 7.52 mmol) was added. The mixture was reacted at room temperature for 3 hours.
[0239] Post-treatment: Diatomaceous earth filtration, concentration, yielding (2R,3S)-3-[4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl]-2-((S)-2-methoxypropamido)butyric acid (69 g). LC-MS: [M+H] + =572.
[0240] Example 1: Synthesis of Compound 1A
[0241] Compound 1-1 was synthesized using the method described in WO2025 / 080986.
[0242] Synthesis of 1-3: (R)-2-(1-(4-bromo-3-fluorophenyl)cyclopropyl)-2-((tert-butoxycarbonyl)amino)acetic acid (1.0 g, 2.57 mmol), benzyl(R)-2-methyl-4-(2-piperazin-1-yl)aminoacetic acid ester (658 mg, 2.82 mmol), HATU (1.17 g, 3.084 mmol), and DIPEA (663 mg, 5.14 mmol) were dissolved in DMF and reacted at room temperature for 1 h. The reaction was quenched with water, extracted with EA (20 mL × 4), the organic phases were combined, washed with saturated brine (20 mL × 3), dried over anhydrous sodium sulfate, filtered and concentrated to give product 1-3, benzyl(R)-4-((R)-2-(1-(4-bromo-3-fluorobenzene)cyclopropyl)-2-((tert-butyloxycarbonyl)amino)acetyl)-2-methylpiperazine-1-carboxylic acid ester 1.24 g, [M+H] + =604.
[0243] Synthesis of 1-4: Benzyl(R)-4-((R)-2-(1-(4-bromo-3-fluorophenyl)cyclopropyl)-2-((tert-butyloxycarbonyl)amino)acetyl)-2-methylpiperazine-1-carboxylic acid ester (604 mg, 1 mmol) was dissolved in 10 mL of DCM, and 10 mL of TFA was added. The reaction was carried out at room temperature for 1 h. The mixture was concentrated, the reaction was quenched with saturated sodium bicarbonate, and extracted with EA (20 mL × 4). The organic phases were combined, washed with saturated brine (20 mL × 1), dried over anhydrous sodium sulfate, filtered, and concentrated to give product 1-4: 0.45 g of benzyl(R)-4-((R)-2-amino-2-(1-(4-bromo-3-fluorophenyl)cyclopropyl)acetyl)-2-methylpiperazine-1-carboxylic acid ester, [M+H]. + =504.
[0244] Synthesis of 1-5: Benzyl(R)-4-((R)-2-amino-2-(1-(4-bromo-3-fluorophenyl)cyclopropyl)acetyl)-2-methylpiperazine-1-carboxylic acid ester (450 mg, 0.89 mmol) was dissolved in 10 mL of pyridine, and (S)-2-methoxypropionic acid (185 mg, 1.78 mmol) was added. The mixture was reacted overnight at room temperature with EDCI (352 mg, 1.78 mmol). Concentrate, add 20 mL of saturated sodium bicarbonate, extract with EA (20 mL × 4), combine the organic phases, wash with saturated brine (20 mL × 1), dry with anhydrous sodium sulfate, filter, concentrate, and purify by reverse column chromatography to obtain products 1-5, benzyl(R)-4-((R)-2-(1-(4-bromo-3-fluorophenyl)cyclopropyl)-2-((S)-2-methoxypropionamide)acetyl)-2-methylpiperazine-1-carboxylic acid ester 0.3 g, [M+H] + =590.
[0245] Synthesis of 1-6: Benzyl(R)-4-((R)-2-(1-(4-bromo-3-fluorophenyl)cyclopropyl)-2-((S)-2-methoxypropionamide)acetyl)-2-methylpiperazine-1-carboxylic acid ester (0.3 g, 0.5 mmol) and tert-butyl(S)-(1-amino-3,3-dicyclopropyl-1-oxopropyl-2-yl)carbamate (63 mg, 0.6 mmol), CuI (95 mg, 0.5 mmol), N,N'-dimethylethylenediamine (44 mg, 0.5 mmol), K3PO4 (415 mg, 1 mmol) were dissolved in dioxane (20 mL), N2 was replaced three times, and then the mixture was heated to 100 °C and reacted overnight under a N2 atmosphere. Filter and add 20 mL of water, then extract with EA (20 mL × 3). Combine the organic phases and purify by reverse column chromatography to obtain 0.25 g of 1-6,benzyl(R)-4-((R)-2-(1-(4-((S)-2-((tert-butyloxycarbonyl)amino)-3,3-dicyclopropylalanine)-3-fluorophenyl)cyclopropyl)-2-((S)-2-methoxyalanine)acetyl)-2-methylpiperazine-1-carboxylic acid ester, [M+H]. + =778.
[0246] Synthesis of 1-7: Benzyl(R)-4-((R)-2-(1-(4-((S)-2-((tert-Butoxycarbonyl)amino)-3,3-dicyclopropylalanine)-3-fluorophenyl)cyclopropyl)-2-((S)-2-methoxyalanine)acetyl)-2-methylpiperazine-1-carboxylic acid ester (0.25 g, 0.32 mmol) was dissolved in 10 mL of DCM, and 10 mL of TFA was added. The reaction was carried out at room temperature for 1 h. The reaction was concentrated, quenched with saturated sodium bicarbonate, and extracted with EA (20 mL × 4). The organic phases were combined, washed with saturated brine (20 mL × 1), dried over anhydrous sodium sulfate, filtered, and concentrated to give products 1-7, 0.15 g of benzyl(R)-4-((R)-2-(1-(4-((S)-2-amino-3,3-dicyclopropylalaninyl)-3-fluorophenyl)cyclopropyl)-2-((S)-2-methoxyalaninyl)acetyl)-2-methylpiperazine-1-carboxylic acid ester, [M+H]. + =678
[0247] Synthesis of 1-8: Benzyl(R)-4-((R)-2-(1-(4-((S)-2-amino-3,3-dicyclopropylalaninyl)-3-fluorophenyl)cyclopropyl)-2-((S)-2-methoxyalaninyl)acetyl)-2-methylpiperazine-1-carboxylic acid ester (0.15 g, 0.22 mmol) was dissolved in 10 mL of DMF, and 1-ethyl-1H-pyrazole-5-carboxylic acid (35 mg, 0.25 mmol), HATU (114 mg, 0.3 mmol), and DIPEA (85 mg, 0.66 mmol) were added. The reaction was carried out at room temperature for 2 h. Add 20 mL of saturated sodium bicarbonate and extract with EA (20 mL × 4). Combine the organic phases and wash with saturated brine (20 mL × 1). Dry with anhydrous sodium sulfate, filter, concentrate, and purify by reverse column chromatography to obtain products 1-8, 0.13 g of benzyl(R)-4-((R)-2-(1-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamide)propionylamino)-3-fluorophenyl)cyclopropyl)-2-((S)-2-methoxypropionylamino)acetyl)-2-methylpiperazine-1-carboxylic acid ester, [M+H] + =800.
[0248] Synthesis of 1-9: Benzyl(R)-4-((R)-2-(1-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamide)propionylamino)-3-fluorophenyl)cyclopropyl)-2-((S)-2-methoxypropionylamino)acetyl)-2-methylpiperazine-1-carboxylic acid ester (0.13 g, 0.16 mmol) was dissolved in THF (10 mL), Pd / C (50 mg) was added, H2 was replaced 5 times, and then the reaction was carried out overnight under H2 atmosphere. Filter under vacuum, wash with 30 mL of methanol, 30 mL of EA, and 30 mL of DCM. Concentrate the filtrate to obtain product 1-9, N-((S)-1,1-dicyclopropyl-3-((2-fluoro-4-(1-((R)-1-((S)-2-methoxypropionylamino)-2-((R)-3-methylpiperazin-1-yl)-2-oxyethyl)cyclopropyl)phenyl)amino)-3-oxopropyl-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide 90 mg, [M+H] + =666.
[0249] Synthesis of Compound 1A: N-((S)-1,1-dicyclopropyl-3-((2-fluoro-4-(1-((R)-1-((S)-2-methoxypropionylamino)-2-((R)-3-methylpiperazin-1-yl)-2-oxyethyl)cyclopropyl)phenyl)amino)-3-oxopropyl-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide (50 mg, 0.07 mmol), dissolved in MeOH (5 mL), with the addition of acetic acid (5 mg) and excess formaldehyde aqueous solution ( 50 mg was added, and the mixture was reacted at room temperature for 1 h. Then, NaBH3CN (9 mg, 0.14 mmol) was added to prepare 20 mg of N-((S)-1,1-dicyclopropyl-3-((4-(1-((R)-2-((R)-3,4-dimethylpiperazin-1-yl)-1-((S)-2-methoxypropionamide)-2-oxyethyl)cyclopropyl)-2-fluorophenyl)amino)-3-oxypropionyl-2-yl)-1-ethyl-1H-pyrazole-5-carbamate, [M+H]. + =680.
[0250] Example 5: Synthesis of Compound 5
[0251] Synthesis of Compound 5: N-((S)-1,1-dicyclopropyl-3-((2-fluoro-4-(1-((R)-1-((S)-2-methoxypropionylamino)-2-((R)-3-methylpiperazin-1-yl)-2-oxyethyl)cyclopropyl)phenyl)amino)-3-oxopropyl-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide (50 mg, 0.07 mmol) was dissolved in MeOH (5 mL), and acetic acid (5 mg) and deuterated paraformaldehyde (5 mL) were added. The reaction was carried out at room temperature for 1 hour, and then NaBH3CN (9 mg, 0.14 mmol) was added to prepare 10 mg of N-((S)-1,1-dicyclopropyl-3-((4-(1-((R)-2-((R)-3,4-dimethylpiperazin-1-yl)-1-((S)-2-methoxypropionamide)-2-oxyethyl)cyclopropyl)-2-fluorophenyl)amino)-3-oxypropionyl-2-yl)-1-ethyl-1H-pyrazole-5-carbamate, [M+H]. + =683.
[0252] Example 9: Synthesis of Compound 9
[0253] Step A:
[0254] Compound 009-1 benzyl N-[(1S)-1-[(4-[(2S,3R)-3-{[(tert-butoxy)carbonyl]amino}-4-[(3S)-3-(fluoromethyl)-4-methylpiperazin-1-yl]-4-oxobut-2-yl]-2-fluorophenyl)carbamoyl]-2,2-dicyclopropylethyl]carbamate (600 mg, 0.84 mmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (4.07 g, 35.71 mmol) was added. The mixture was stirred at room temperature for 2 h.
[0255] The solvent was evaporated to dryness, the reaction was quenched with saturated sodium bicarbonate aqueous solution, extracted with EA, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. Column chromatography (dichloromethane:methanol = 10:1) gave a yellow oily liquid product 009-2, namely benzyl N-[(1S)-1-[(4-[(2S,3R)-3-amino-4-[(3S)-3-(fluoromethyl)-4-methylpiperazin-1-yl]-4-oxobut-2-yl]-2-fluorophenyl)carbamoyl]-2,2-dicyclopropylethyl]carbamate (500 mg) (yield 97%). LC-MS: [M+H] + =612.
[0256] Step B:
[0257] Dissolve 009-2 (500 mg, 0.82 mmol) in dichloromethane (20 mL), add triethylamine (0.41 g, 4.1 mmol) and 2-methoxyacetyl-2-methoxyacetate (0.20 g, 1.23 mmol), and stir at room temperature for 1 h.
[0258] The reaction was quenched with water, extracted with dichloromethane, dried over anhydrous sodium sulfate, and filtered and evaporated to dryness to give 009-3, namely benzyl N-[(1S)-2,2-dicyclopropyl-1-[(2-fluoro-4-[(2S,3R)-4-[(3S)-3-(fluoromethyl)-4-methylpiperazin-1-yl]-3-(2-methoxyacetamide)-4-oxobut-2-yl]phenyl)carbamoyl]ethyl]carbamate (550 mg) (yield 98%). LC-MS: [M+H] + =684.
[0259] Step C:
[0260] Dissolve 009-3 (550 mg, 0.80 mmol) in methanol (10 mL), add palladium on carbon (532.95 mg, 5.01 mmol), replace with hydrogen three times, and stir at room temperature for 1 h under a hydrogen atmosphere.
[0261] The product was filtered and evaporated to dryness to give a yellow liquid product 009-4, namely (2S)-2-amino-3,3-dicyclopropyl-N-(2-fluoro-4-[(2S,3R)-4-[(3S)-3-(fluoromethyl)-4-methylpiperazin-1-yl]-3-(2-methoxyacetamide)-4-oxobut-2-yl]phenyl)propionamide (440 mg) (yield 99%). LC-MS: [M+H] + =550.
[0262] Step D:
[0263] At room temperature, 3,3-difluorocyclobutane-1-ol (0.088 g, 0.81 mmol), N,N'-disuccinimide (0.21 g, 0.81 mmol), and triethylamine (0.16 g, 1.62 mmol) were dissolved in acetonitrile (5 mL) and stirred at room temperature for 1.5 h. The mixture was then slowly added dropwise to a solution of 001-4 (150 mg, 0.27 mmol) dissolved in N,N-dimethylformamide (5 mL) and reacted at room temperature for 1 h.
[0264] The reaction was quenched with water, extracted with EA, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. Preparative chromatography purification yielded 3,3-difluorocyclobutyl N-[(1S)-2,2-dicyclopropyl-1-[(2-fluoro-4-[(2S,3R)-4-[(3S)-3-(fluoromethyl)-4-methylpiperazin-1-yl]-3-(2-methoxyacetamide)-4-oxobut-2-yl]phenyl)carbamoyl]ethyl]carbamate (74 mg, yield 40%). LC-MS: [M+H] + =684, 1HNMR(400MHz, DMSO-d6)δ9.70(s,1H),7.97(dd,J=21.7,8.7Hz,1H),7.79-7.68(m,1H),7.54(d,J=9.0Hz,1H),7.19-7.12(m,1H), 7.04(t,J=9.5Hz,1H),4.96(q,J=8.9Hz,1H),4.81(s,1H),4.45(d,J=3.5Hz,2H),4.35-4.22(m,1H),3.85(s,4H),3.15-3.08(m,1 H),3.03(s,2H),2.82(t,J=12.1Hz,1H),2.69-2.60(m,2H),2.18(s,1H),2.01(s,3H),1.54-1.37(m,1H),1.23(d,J=6.9Hz,6H),1 .19(s,1H),0.96-0.74(m,3H),0.60-0.52(m,1H),0.45(s,1H),0.35(s,1H),0.25(d,J=8.5Hz,2H),0.16(dd,J=11.5,5.2Hz,4H).
[0265] Example 28: Synthesis of compound 28A
[0266] Synthesized N-((S)-1,1-dicyclopropyl-3-((4-(((2S,3R)-4-((S)-3-(difluoromethyl)-4-methylpiperazin-1-yl)-3-((S)-2-methoxypropamido)-4-oxobutane-2-yl)-2-fluorophenyl)amino)-3-oxopropane-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide (Compound 27A)
[0267] At room temperature, (2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carbamoyl)propamido)-3-fluorophenyl)-2-((S)-2-methoxypropamido)butyric acid (200 mg, 0.35 mmol) was dissolved in N,N-dimethylformamide (5 mL), and (S)-2-(difluoromethyl)-1-methylpiperazine dihydrochloride (94 mg, 0.42 mmol), N,N-diisopropylethylamine (0.29 mL, 1.75 mmol), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (200 mg, 0.52 mmol) were added, and the mixture was stirred at room temperature for 1 hour.
[0268] Post-treatment: Add saturated sodium bicarbonate aqueous solution (20 mL), extract with ethyl acetate (25 mL × 3), combine the organic phases, wash with saturated brine (20 mL × 1), dry the organic phase with anhydrous sodium sulfate, filter, concentrate the filtrate to dryness, and purify to give 68 mg of N-((S)-1,1-dicyclopropyl-3-((4-(((2S,3R)-4-((S)-3-(difluoromethyl)-4-methylpiperazin-1-yl)-3-((S)-2-methoxypropamido)-4-oxobutane-2-yl)-2-fluorophenyl)amino)-3-oxopropane-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide (yield 27%). LC-MS: [M+H] + =704.
[0269] 1 HNMR (400MHz, DMSO-d6) δ9.94(d,J=19.3Hz,1H),8.44(dd,J=9.0,3.0Hz,1H),8.19(t,J=7.5Hz,1H),7.78(dt,J=11.4,8.3H z,1H),7.48(d,J=1.8Hz,1H),7.14(dd,J=12.4,4.7Hz,1H),7.08-6.95(m,2H),6.28-5.64(m,1H),4.89(dt,J=48.9,8.8Hz, 2H),4.47(qd,J=7.1,4.5Hz,2H),3.94-3.74(m,3H),3.21(s,3H),3.06-2.89(m,1H),2.82-2.54(m,2H),2.37-2.02(m,4H), 1.57-1.37(m,1H),1.32-1.14(m,10H),0.95-0.80(m,2H),0.75(t,J=9.2Hz,1H),0.46(t,J=6.9Hz,1H),0.39-0.11(m,7H).
[0270] Synthetic compound 28B
[0271] N-((S)-1,1-Dicyclopropyl-3-((4-((2S,3R)-4-((R)-3-(difluoromethyl)-4-methylpiperazin-1-yl)-3-((S)-2-methoxypropamido)-4-oxobutane-2-yl)-2-fluorophenyl)amino)-3-oxopropane-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide
[0272] At room temperature, (2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carbamoyl)propamido)-3-fluorophenyl)-2-((S)-2-methoxypropamido)butyric acid (200 mg, 0.35 mmol) was dissolved in N,N-dimethylformamide (5 mL), and (R)-2-(difluoromethyl)-1-methylpiperazine dihydrochloride (94 mg, 0.42 mmol), N,N-diisopropylethylamine (0.29 mL, 1.75 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (200 mg, 0.52 mmol) were added, and the mixture was stirred at room temperature for 1 hour.
[0273] Post-treatment: Add saturated sodium bicarbonate aqueous solution (20 mL), extract with ethyl acetate (25 mL × 3), combine the organic phases, wash with saturated brine (20 mL × 1), dry the organic phase with anhydrous sodium sulfate, filter, concentrate the filtrate to dryness, and purify to give 73 mg of N-((S)-1,1-dicyclopropyl-3-((4-(((2S,3R)-4-((R)-3-(difluoromethyl)-4-methylpiperazin-1-yl)-3-((S)-2-methoxypropamido)-4-oxobutane-2-yl)-2-fluorophenyl)amino)-3-oxopropane-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide (yield 29%). LC-MS: [M+H] + =704.
[0274] 1 HNMR (400MHz, DMSO-d6) δ9.94(d,J=16.0Hz,1H),8.44(d,J=8.9Hz,1H),8.23(dd,J=17.1,8.6Hz,1H),7.76(q,J=8 .3Hz,1H),7.48(d,J=2.0Hz,1H),7.23-6.95(m,3H),6.32-5.87(m,1H),4.91(dt,J=33.2,8.8Hz,2H),4.47(qd,J= 6.8,4.1Hz,2H),3.93-3.56(m,3H),3.24-3.10(m,5H),2.78(dd,J=13.2,8.9Hz,1H),2.69-2.55(m,1H),2.17(d,J =52.3Hz,3H),2.08-1.80(m,1H),1.50-1.14(m,10H),0.94-0.68(m,3H),0.45(d,J=7.4Hz,1H),0.54-0.12(m,7H).
[0275] Example 40
[0276] Synthesis of N-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazol-5-carboxamido)propamido)-3-fluorophenyl)-1-(((R)-3,4-dimethylpiperazin-1-yl)-1-oxobut-2-yl)-1-ethyl-1H-pyrrole-5-carboxamide
[0277] Step A: N-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-1-(((R)-3,4-dimethylpiperazin-1-yl)-1-oxobut-2-yl)-1-ethyl-1H-pyrrole-5-carboxamide
[0278] At room temperature, N-((S)-1-((4-(2S,3R)-3-amino-4-((R)-3,4-dimethylpiperazin-1-yl)-4-oxobut-2-yl)-2-fluorophenyl)amino)-3,3-dicyclopropyl-1-oxopropyl-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide (100 mg, 0.17 mmol), 1-ethyl-1H-pyrazole-5-carboxylic acid (36.14 mg, 0.26 mmol) and DIEA (111 mg, 0.859 mmol) were dissolved in DMF (2 mL), and then HATU (104 mg, 0.275 mmol) was added. The mixture was reacted at room temperature for 2 hours.
[0279] After the reaction was complete, 30 mL of H₂O was added. The mixture was extracted with ethyl acetate (3 x 30 mL), the organic phases were combined, washed with saturated brine (3 x 20 mL), dried over anhydrous Na₂SO₄, filtered, and rotary evaporated to the residue. The residue was purified by C18 reversed-phase column chromatography (ACN / 1% NH₃·H₂O, 55% ACN) to give N-((2R, 3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-1-(((R)-3,4-dimethylpiperazin-1-yl)-1-oxobut-2-yl)-1-ethyl-1H-pyrrole-5-carboxamide (74 mg, yield 60%). LC-MS: [M+H] + =704.
[0280] 1HNMR (400MHz, DMSO-d6) δ9.92(d,J=9.7Hz,1H),8.84(dd,J=16.5,8.3Hz,1H),8.42(d,J=8.9Hz,1H),7.79(dt,J=33 .0,8.3Hz,1H),7.51-7.42(m,2H),7.17(t,J=13.4Hz,1H),7.11-6.94(m,3H),5.07(q,J=10.3Hz,1H),4.95(q,J=8.3 Hz,1H),4.47(dp,J=13.7,6.6Hz,4H),4.03-3.71(m,2H),2.84-2.56(m,1H),2.45(s,1H),2.22-1.68(m,4H),1.27( t,J=7.2Hz,11H),0.91(s,1H),0.83(d,J=8.7Hz,4H),0.76(dd,J=11.4,7.3Hz,2H),0.46(s,1H),0.38-0.13(m,7H).
[0281] Example 45: Synthesis of compound 45A
[0282] The synthetic route for (S)-22-carboxy-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazol-5-carboxamido)propamido)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-ylamino)propamido)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraone-3,6,12,15-tetraoxo-9,18,23-triazatetratetradecane-41-carboxylic acid is as follows:
[0283] Step A: Synthesis of tert-butyl(R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((S)-2-(2-aminopyrimidine)propamido)butyryl)-2-methylpiperazine-1-carboxylic acid ester. At room temperature, (2R,3S)-3-(4-((S) 3,3-Dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-amino)propamido)butyric acid (50 mg, 78.8 μmol, 1 eq) and tert-butyl(R)-2-methylpiperazine-1-carboxylic acid ester (15.78 mg, 78.8 μmol, 1 eq) were dissolved in 10 mL of N,N-dimethylformamide (DMF) solution. Under nitrogen protection, N,N-diisopropylethylamine (DIPEA) (40.73 mg, 315.11 μmol, 55.1 μL, 4 eq) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (HATU) (44.93 mg, 118 μmol, 1.5 eq) were added. The reaction solution was stirred at 25°C for 2 hours.
[0284] Post-treatment: The reaction solution was extracted with water and dichloromethane. The organic phase was evaporated to dryness under normal phase (dichloromethane:MeOH = 8:1) to give (tert-butyl(R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((S)-2-(2-aminopyrimidine)propamido)butyryl)-2-methylpiperazine-1-carboxylic acid ester) (50 mg). LC-MS: [M+H] + =817.
[0285] Step B: Synthesis of N-((S)-1,1-dicyclopropyl-3-((2-fluoro-4-((2S,3R)-4-((R)-3-methylpiperazin-1-yl)-4-oxo-3-((S)-2-(pyrimidin-2-ylamino)propionylamino)butyl)phenyl)amino)-3-oxopropane-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide
[0286] At room temperature, tert-butyl(R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((S)-2-(2-aminopyrimidine)propamido)butyryl)-2-methylpiperazine-1-carboxylic acid ester (50 mg) was added to dichloromethane (10 mL), followed by the addition of trifluoroacetic acid (TFA) (210 mg, 1.84 mmol, 30 eq), and the mixture was stirred at room temperature for 1 hour.
[0287] Post-treatment: The reaction solution was directly evaporated to dryness to obtain a yellow oily crude compound (N-((S)-1,1-dicyclopropyl-3-((2-fluoro-4-((2S,3R)-4-((R)-3-methylpiperazin-1-yl)-4-oxo-3-((S)-2-(pyrimidin-2-ylamino)propionylamino)butyl)phenyl)amino)-3-oxopropane-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide) (43 mg), which was used directly in the next step. LC-MS: [M+H] + =717.
[0288] Step C: Synthesis of tert-butyl(S)-22-(tert-butoxycarbonyl)-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamide)propionamide)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-ylamino)propionamide)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraone-3,6,12,15-tetraoxo-9,18,23-triazatetrazane-41-ester
[0289] At room temperature, N-((S)-1,1-dicyclopropyl-3-((2-fluoro-4-((2S,3R)-4-((R)-3-methylpiperazin-1-yl)-4-oxo-3-((S)-2-(pyrimidin-2-ylamino)propionylamino)butyl)phenyl)amino)-3-oxopropane-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide (43 mg) was dissolved in DMF (10 mL), and then compound A (60.9 mg, 71.9 μmol, 1.2 eq), HATU (34.21 mg, 89.9 μmol, 1.5 eq), and DIPEA (46.5 mg, 360 μmol, 6 eq) were added. The reaction solution was then stirred at 25 °C for 2 hours.
[0290] Post-treatment: The reaction solution was extracted with water and dichloromethane. The organic phase was evaporated to dryness and passed through a normal phase (DCM:MeOH = 10:1) to give (tert-butyl(S)-22-(tert-butoxycarbonyl)-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazol-5-carboxamide)propionamide)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-ylamino)propionamide)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraone-3,6,12,15-tetraoxo-9,18,23-triazatetracoane-41-ester) (50 mg). LC-MS: [M+H) + =1545.
[0291] Step D: Synthesis of (S)-22-carboxy-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazol-5-carboxamido)propamido)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-ylamino)propamido)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraone-3,6,12,15-tetraoxo-9,18,23-triazatetratetradecane-41-carboxylic acid
[0292] At room temperature, tert-butyl(S)-22-(tert-butoxycarbonyl)-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamide)propionamide)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-ylamino)propionamide)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraone-3,6,12,15-tetraoxo-9,18,23-triazatetrazane-41-ester (50 mg) was dissolved in DCM (10 mL), followed by the addition of TFA (184 mg, 1.62 mmol, 50 eq), and stirred at room temperature for 1 hour.
[0293] Post-treatment: The reaction solution was directly evaporated to dryness to obtain crude product. Then, using an ammonia system, ((S)-22-carboxy-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazol-5-carboxamido)propamido)-3-fluorophenyl)-2-((S)-2-(pyrimidin-2-ylamino)propamido)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraone-3,6,12,15-tetraoxo-9,18,23-triazatetratetradecane-41-carboxylic acid) (18.2 mg) was obtained. LC-MS: [M+H] + =1444.
[0294] 1 HNMR: (δ9.93(s,1H),8.50(s,1H),8.38-8.10(m,3H),7.93(s,1H),7.86-7.61(m,3H),7.47(s,1H),7.23-6.91(m,4H),6.60(t, J=4.9Hz,1H),4.97(d,J=41.6Hz,2H),4.45(dq,J=14.3,7.1Hz,3H),4.01(t,J=14.7Hz,4H),3.87(s,2H),3.64-3.45(m,10H),3. 40(q,J=6.5Hz,3H),3.19(t,J=5.7Hz,2H),2.18(t,J=7.3Hz,2H),2.09(q,J=7.8Hz,4H),2.00(d,J=7.7Hz,1H),1.89(d,J=7.6H z,1H),1.75(s,1H),1.46(s,5H),1.38-1.20(m,40H),1.13(d,J=6.8Hz,3H),0.95-0.63(m,5H),0.32(dd,J=67.8,34.5Hz,14H).
[0295] Synthetic compound 45B
[0296] The synthetic route of compound 45B was prepared by referring to the preparation route of compound 45A.
[0297] Example 46: Synthesis of Compound 46
[0298] The synthetic route for (S)-22-carboxy-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((R)-2-methoxypropamido)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraoxo-3,6,12,15-tetraoxa-9,18,23-triazatetradecane-41-acid is as follows:
[0299] Step A: Synthesis of tert-butyl(R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((R)-2-methoxypropamido)butyryl)-2-methylpiperazine-1-carboxylic acid ester
[0300] At room temperature, (2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((S)-2-methoxypropamido)butyric acid (50 mg, 87.47 μmol, 1 eq) and (R)-1-N-Boc-2-methylpiperazine (21.02 mg, 104.96 μmol, 1.2 eq) were dissolved in 2 mL of DMF. Under nitrogen protection, DIPEA (67.83 mg, 524.81 μmol, 6 eq) and HATU (49.89 mg, 131.20 μmol, 1.5 eq) were added. The reaction mixture was stirred at 25 °C for 1 hour.
[0301] Post-treatment: Dilute the reaction solution with 5 mL of ethyl acetate, add 15 mL of saturated sodium bicarbonate solution, extract with ethyl acetate (5 mL * 3), wash the collected organic phase with 10 mL of saturated brine, dry with anhydrous sodium sulfate, filter, and concentrate under reduced pressure to obtain the crude product, a yellow oily compound tert-butyl(R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((R)-2-methoxypropamido)butyryl)-2-methylpiperazine-1-carboxylic acid ester (65.94 mg, 87.54 μmol). LC-MS: [M-Boc+H] + =654.6.
[0302] Step B: Synthesis of N-((S)-1,1-dicyclopropyl-3-((2-fluoro-4-((2S,3R)-3-((R)-2-methoxypropamido)-4-((R)-3-methylpiperazin-1-yl)-4-oxobutane-2-yl)phenyl)amino)-3-oxopropane-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide
[0303] At room temperature, tert-butyl(R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((R)-2-methoxypropamido)butyryl)-2-methylpiperazine-1-carboxylic acid ester (65.94 mg, 87.54 μmol) was dissolved in 2 ml of DCM. Under nitrogen protection, 1 ml of TFA was added. The reaction mixture was stirred at 25 °C for 30 min.
[0304] Post-treatment: The reaction solution was concentrated under reduced pressure to obtain the crude product, a yellow oily compound N-((S)-1,1-dicyclopropyl-3-((2-fluoro-4-((2S,3R)-3-((R)-2-methoxypropamido)-4-((R)-3-methylpiperazin-1-yl)-4-oxobutane-2-yl)phenyl)amino)-3-oxopropane-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide (57.24 mg, 87.55 μmol). LC-MS: [M+H] + =654.6.
[0305] Step C: Synthesis of tert-butyl(S)-22-(tert-butoxycarbonyl)-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carbamoyl)propamido)-3-fluorophenyl)-2-((R)-2-methoxypropamido)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraoxo-3,6,12,15-tetraoxa-9,18,23-triazatetradecane-41-ester
[0306] At room temperature, N-((S)-1,1-dicyclopropyl-3-((2-fluoro-4-((2S,3R)-3-((R)-2-methoxypropamido)-4-((R)-3-methylpiperazin-1-yl)-4-oxobutane-2-yl)phenyl)amino)-3-oxopropane-2-yl)-1-ethyl-1H-pyrazole-5-carboxamide (57.24 mg, 87.55 μmol, 1 eq) and compound A (88.89 mg, 105.06 μmol, 1.2 eq) were dissolved in 2 mL of DMF. Under nitrogen protection, DIPEA (67.83 mg, 524.81 μmol, 6 eq) and HATU (49.89 mg, 131.20 μmol, 1.5 eq) were added. The reaction mixture was stirred at 25 °C for 24 hours.
[0307] Post-processing: The reaction solution was directly purified by reversed-phase column chromatography (column: Phenomenex Luna C18 150*25mm*10um; mobile phase: [water (0.1% TFA)-ACN]; gradient: 5%-100% B over). After 50 min, tert-butyl(S)-22-(tert-butoxycarbonyl)-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carbamoyl)propamido)-3-fluorophenyl)-2-((R)-2-methoxypropamido)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraoxo-3,6,12,15-tetraoxa-9,18,23-triazatetradecane-41-ester (23 mg, 15.53 μmol) was obtained. LC-MS: [(M+H) / 2] + =741.2.
[0308] Step D: Synthesis of (S)-22-carboxy-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((R)-2-methoxypropamido)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraoxo-3,6,12,15-tetraoxa-9,18,23-triazatetradecane-41-acid
[0309] At room temperature, 23 mg (15.53 μmol) of tert-butyl(S)-22-(tert-butoxycarbonyl)-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((R)-2-methoxypropamido)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraoxo-3,6,12,15-tetraoxa-9,18,23-triazatetrazane-41-ester (23 mg, 15.53 μmol) was dissolved in 2 mL of DCM. Under nitrogen protection, 1 mL of TFA was added. The reaction mixture was stirred at 25 °C for 1 hour.
[0310] Post-treatment: After concentration under reduced pressure, the reaction solution was purified to obtain (S)-22-carboxy-1-((R)-4-((2R,3S)-3-(4-((S)-3,3-dicyclopropyl-2-(1-ethyl-1H-pyrazole-5-carboxamido)propamido)-3-fluorophenyl)-2-((R)-2-methoxypropamido)butyryl)-2-methylpiperazin-1-yl)-1,10,19,24-tetraoxo-3,6,12,15-tetraoxa-9,18,23-triazatetradecane-41-acid (12 mg, 8.75 μmol). LC-MS: [(M+H) / 2] + =685. 1 HNMR: (400MHz, CDCl3) δ9.92(s,2H),8.45(d,J=9.0Hz,1H),7.91(s,2H),7.47(s,1H),7.16(d,J=6.8Hz,1H),7.00 (s,1H),5.32(m,1H),4.93(m,1H),4.47(m,2H),3.87(m,2H),3.79(d,J=6.7Hz,1H),3.71(s,1H),3.59-3.47(m,11H ),3.21(d,J=7.1Hz,3H),3.01(s,2H),2.67(d,J=2.4Hz,3H),2.33(s,3H),2.18(t,J=7.4Hz,2H),2.10(m,4H),2.00 (d,J=7.8Hz,1H),1.74(d,J=12.2Hz,1H),1.47(s,5H),1.23(s,52H),0.85(d,J=7.5Hz,1H),0.73(d,J=8.5Hz,1H).
[0311] The preparation routes of the compounds in Tables 1 and 2 can be synthesized by referring to the preparation methods described in Examples 1, 5, 9, 28, 40, 45, 46, and patent documents CN202080079537.5, CN202380035861.0, WO2025209395A1, and WO2025 / 080986, which can also be incorporated herein by reference in their entirety.
[0312] Table 1. Compound Structures
[0313] Table 2
[0314] Example 58: HT-29 Cell Human IL-17A Neutralization Experiment
[0315] The activity of the compound against human IL-17A at the cellular level was evaluated using HT-29 cells. The specific experimental steps are as follows:
[0316] 1. Take HT-29 cells in the logarithmic growth phase, remove the original culture medium, wash the cells with PBS, add trypsin to digest for 3 min, centrifuge (1000 rpm, add trypsin), discard the supernatant, resuspend in 3 ml, take 100g of the suspension, dilute 10-fold, count, and then count by 2. 5 Cells were seeded at 1 / ml in 96-well plates (#3596; Costar) and cultured as adherent cells for 24 hours.
[0317] 2. Discard the original culture medium and add normal culture medium, culture medium containing different concentrations of the compound (initial concentration 1, 4-fold dilution) and 30 ng / ml or 90 ng / ml human IL-17A, and culture medium containing 30 ng / ml or 90 ng / ml human IL-17A and different concentrations of secukinumab (initial concentration 10 nM, 5-fold dilution) to the plate.
[0318] 3. Continue incubation for 48 hours, then collect the supernatant.
[0319] 4. The CXCL1 / GROa in the culture medium was detected using a commercially available ELISA kit (#DGR00B, R&D Systems). (Wells containing only culture medium were used as the bottom values for CXCL1 / GROa).
[0320] The inhibition rate is calculated using the following formula:
[0321] 5. The experimental results were fitted and analyzed using Prism, and the IC50 of the compounds was calculated. 50 The IC50 values, measured using 30 ng / ml human IL-17A culture medium, are shown in Table 3. The results indicate that the compound of this invention exhibits excellent inhibitory activity relative to IL-17A, and the preferred compound has an IC50 value of [missing value]. 50 Less than 100 nM.
[0322] Table 3
[0323] Example 59: HEK-blue cell assay for IL-17AA inhibitory activity
[0324] 1. Main materials and reagents
[0325] 2. Experimental apparatus
[0326] 3. Experimental methods and procedures
[0327] (1) Reconstitution of human IL-17AA, Recombinant Human IL-17A / F Heterodimer Protein and its packaging
[0328] 1.1 Gently tap the vials containing human IL-17A and Recombinant Human IL-17A / F Heterodimer Protein solid powder respectively to ensure that all samples are at the bottom of the vials.
[0329] 1.2 Dissolve human IL-17A and human IL-17A / F in 250 μL or 500 μL of 4 mM HCl under sterile conditions. Gently shake the bottle until all the solids in the bottle dissolve into a colorless and transparent liquid.
[0330] 1.3 Aliquot the dissolved liquid into 10 μL tubes and store the aliquots at -80°C to avoid repeated freeze-thaw cycles. The solution concentration is 100 μg / mL; further dilution is required before use.
[0331] (2) Experimental steps
[0332] Day 0
[0333] 2.1 Cell Preparation: Remove the culture medium, add 3 mL of PBS, and gently shake the culture flask to detach the adherent cells. Resuspend the cells in culture medium containing inactivated FBS and adjust the cell density to 2.2 × 10⁻⁶ cells / mL. 5 per mL.
[0334] 2.2 Add 180 μl of a solution with a density of 2.2 × 10⁻⁶. 5 Add cells per mL to a 96-well plate.
[0335] 2.3 Add 10 μL of the compound to a 96-well plate.
[0336] 2.4 Add 10 μL of IL-17A or IL-17A / F working solution (final concentration 3 ng / mL)
[0337] 2.5 Negative control wells: Cell control wells containing no IL17A or IL-17A / F.
[0338] 2.6 Set up positive control wells: control wells containing IL17A or IL-17A / F (final concentration 3 ng / mL) cells.
[0339] 2.7 The culture plates were incubated at 37°C in a carbon dioxide incubator for 18 hours.
[0340] Day 1:
[0341] 2.8 Take a 96-well black transparent plate, add 25 μL of Tropix@Phospha-Light analysis buffer to each well, then add 25 μL of cell supernatant, and incubate at room temperature for 5 min.
[0342] 2.9 Add 25 μL of Tropix@Phospha-Light Reaction Buffer to each well and incubate at room temperature for 20 min.
[0343] 2.10 Use an enzyme-linked immunosorbent assay (ELISA) reader to detect chemiluminescence.
[0344] (3) Data Analysis
[0345] 3.1 Subtract the blank control value from all readings
[0346] 3.2 The inhibition rate is calculated using the following formula.
[0347] Formula for calculating inhibition rate % = 100 Control -RFU compound ) / RFU Control
[0348] The IC was obtained by fitting the logarithm of compound concentration on the x-axis and the inhibition rate on the y-axis using Graphpad Prism. 50 The values are shown in Tables 4 and 5. The results indicate that the compounds of the present invention have good inhibitory activity against IL-17AA and / or IL-17AF, preferably IC50. 50 ≤100nM.
[0349] Table 4 shows the inhibitory activity of IL-17AA.
[0350] Table 5 shows the inhibitory activity of IL-17AF.
[0351] Example 60 Pharmacokinetic Experiment
[0352] 1. Experimental Materials
[0353] SD rats: male, 180-250g, purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd.
[0354] Reagents: DMSO (dimethyl sulfoxide), PEG-400 (polyethylene glycol 400), physiological saline, heparin, acetonitrile, formic acid, and propranolol (internal standard) were all commercially available. Instrument: AB SCIEX QTRAP 5500+.
[0355] 2 Experimental Methods
[0356] The compound was dissolved in a DMSO-PEG-400-physiological saline (5:60:35, v / v / v) system. After intravenous (iv) or gavage (ig) administration to rats, 200 μL of venous blood was collected at 15 min, 30 min, 1 h, 2 h, 5 h, 7 h, and 24 h (an additional 5 min was collected for the iv group) in EDTA-K2 anticoagulant tubes. The tubes were centrifuged at 12000 rpm for 2 min, and the plasma was stored at -80℃ for later analysis. A precise amount of the test sample was dissolved in DMSO to a concentration of 2 mg / mL to prepare a stock solution. An appropriate amount of the stock solution was accurately pipetted and diluted with acetonitrile to prepare a series of standard solutions. Accurately pipette 10 μL of each of the above standard series solutions, add 90 μL of blank plasma, vortex to mix, and prepare plasma samples with concentrations equivalent to 1, 3, 5, 10, 30, 100, 300, 1000, and 3000 ng / mL. Perform dual-sample analysis for each concentration to establish a standard curve. Take 30 μL of plasma (diluted 5-fold after intravenous administration at 5 min, 15 min, and 30 min), add 150 μL of acetonitrile solution of propranolol (50 ng / mL) as internal standard, vortex to mix, add 100 μL of purified water, vortex again, centrifuge at 4000 rpm for 5 min, and analyze the supernatant by LC-MS. The LC-MS detection conditions are as follows:
[0357] Chromatographic column: YMC Triart C18, 50*3.0mm, 2.1μm.
[0358] Mobile phase: Water (0.1% formic acid) - acetonitrile. Gradient elution is performed according to the table below:
[0359] 3 Data Processing
[0360] After detecting the blood drug concentration by LC-MS, the pharmacokinetic parameters were calculated using WinNonlin 6.1 software and the non-compartmental model method. The results are shown in Table 6. The results indicate that the compound of the present invention has a good in vivo exposure.
[0361] Table 6
[0362] Example 61: Pharmacological Experiment
[0363] Experimental Methods: SD rats were divided into 6 groups (n=6 per group): normal control group, model group, and compound treatment group (50 mg / kg). IL-23 protein was injected intradermally into the ear skin for 5 consecutive days to induce local psoriatic lesions. During the modeling period, rats were treated with oral administration of IL-23 protein at doses of 15 mg / kg, 25 mg / kg, 50 mg / kg, or 100 mg / kg, twice daily for 5 consecutive days. Ear thickness was measured on Day 2-Day 5 during the modeling period.
[0364] Dosing group
[0365] Experimental results: After induction with IL-23 protein, the ear thickness of the model group increased significantly, indicating successful model establishment. The results show that administration of the preferred compound N of this invention produced a significant protective effect on the ear skin of rats, and the ear thickness of the rats was significantly reduced.
[0366] Example 62: Evaluation of the efficacy of collagen-induced arthritis in rats
[0367] Experimental Methods: Female Lewis rats were used in the experiment. Modeling was initiated after the rats had acclimatized. Bovine type II collagen was mixed with an equal volume of incomplete Freund's adjuvant (IFA), emulsified, and the model was established through two intradermal injections of the collagen-adjuvant mixture. The first immunization was performed using a three-point injection method: at the base of the tail, the back, and the plantar surface of the paws. A second booster immunization was administered 7 days after the first immunization, using the same method. At the time of the second immunization, the paw volume of the left and right forelimbs was measured, and the average value was used as a reference. Three to six days after the second immunization, rats were grouped based on a 10% increase in paw volume relative to the reference value and a clinical observation score of 1 or higher (appearance of red dots or nodules on the ears, nose, tail, and limbs). Animals were randomly assigned to groups of eight: a model group, a low-dose compound N group, and a high-dose compound N group. A normal control group was also included. After grouping, drug administration began. All groups were administered the drug or solvent via gavage twice daily for 10 days. After administration, the hind paw volume of rats in each group was measured twice a week using a toe volume analyzer.
[0368] The results showed that the preferred compound N could improve the paw volume of arthritic rats, demonstrating anti-inflammatory and symptom-improving effects.
[0369] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.
Claims
1. The compound of formula (I) or its racemate, isomer, or pharmaceutically acceptable salt thereof, characterized in that, wherein a, b are independently selected from 0 or 1, m is selected from 0, 1, 2, 3 or 4, Y is selected from CH, N, O, S, when Y is selected from O, S, R 1 is absent; Z is selected from C, CH, N; A ring is selected from substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R A substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R A is selected from hydrogen, alkyl, halogen, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, haloalkenyl, halocycloalkyl, -O-cycloalkyl; X 1 X 2 Selected independently from hydrogen, or X 1 , X 2 together cyclize to a substituted or unsubstituted heterocycloalkyl or heteroaryl, the substituted substituent being selected from the group consisting of alkyl, halogen; R X1 R X2 It is selected alone from alkyl, alkenyl, alkynyl, nitrile, alkylnitrile, halogen, haloalkyl, haloalkenyl, NT1T2, or substituted or unsubstituted -(CH2). c -N T1T2, -alkyl-O-alkyl, -alkyl-O-cycloalkyl, -alkyl-NH-aryl, -alkyl-NH-heteroaryl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH2) f -cycloalkyl, -(CH2) e -O-alkyl, -(CH2) p -O-cycloalkyl, alkyl heterocyclic alkyl, halocyclic heterocyclic alkyl, -CT3T4-O-alkyl, saturated or unsaturated C 5-12 Ring, C 5-12 Heterocyclic, wherein the substitution is selected from alkyl, cycloalkyl, alkoxy, halogen, haloalkyl, wherein T1, T2, T3, T4 are individually selected from hydrogen, halogen, nitrile, alkyl, haloalkyl, alkoxy, cycloalkyl, heterocyclic alkyl, or T1 and T2, T3 and T4 together cyclized to substituted or unsubstituted cycloalkyl, heterocyclic alkyl, wherein the substitution is selected from alkyl, halogen, alkoxy, wherein c, f, e, p are selected from 1, 2, 3, 4, 5 or 6; R 1 Selected from hydrogen, alkyl, alkoxy, halogen, and haloalkyl; R 2 Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2b The substituent is selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkenyl groups, and the R group is selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkenyl groups. 2a and R 2b Independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups; R 3 Selected from hydrogen, halogen, alkyl, and alkoxy groups; R 4a R 4b Selected independently from hydrogen, alkyl, halogen, nitrile, alkoxy, haloalkyl, cycloalkyl, or, R 4a R 4b Together they are cyclically converted into at least one R k Substituted cycloalkyl or heterocycloalkyl, wherein the substitution is selected from hydrogen, alkyl, halogen, haloalkyl, or alkoxy; R 5 and R 6 It is selected independently from alkyl, alkoxy, cycloalkyl, -AEEA-AEEA-γE-CO-(CH2) t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, wherein the substituent is selected from hydrogen, alkyl, halogen, haloalkyl, -NH2; Or, R 5 and R 6 Together they are cyclically converted into at least one R a Substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R a Selected from hydrogen, alkyl, alkoxy, nitrile, alkylnitrile, halogen, cycloalkyl, alkylsulfonyl, alkoxycarbonyl, alkylamino, -alkyl-O-alkyl, haloalkyl, haloalkenyl, -AEEA-AEEA-γE-CO-(CH2) t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, wherein the substituent is selected from hydrogen, alkyl, halogen, haloalkyl, -NH2, and the substitution is at least one, wherein u and v are individually selected from 1, 2, 3, 4, 5 or 6, and t is selected from positive integers from 8 to 20; Or R 5 and R 6 Together they become a ring m1, m2, and m3 are each selected from 0, 1, or 2. W is selected from N, CH, O, and S. When W is selected from O or S, R... 9 It does not exist, R 7 and R 8 Selected independently from hydrogen, alkyl, haloalkyl, or R 7 and R 8 Together they cyclize into substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups, wherein the substitution is selected from alkyl, alkoxy, halogen, haloalkyl, or cycloalkyl groups, and at least one substitution is performed. R 9 Selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, and cycloalkyl.
2. The compound according to claim 1, or its racemate, its isomer, or its pharmaceutically acceptable salt, characterized in that, When a is 0 and b is 1, X 2 For hydrogen, R 5 and R 6 Together they become a ring When Z is selected from N, it is selected from the structure shown in equation (II). Among them, m1, m2, and m3 are individually selected from 0, 1, or 2; m can be 0, 1, 2, 3, or 4; W is selected from O, N, and S. When X is selected from O and S, R 9 It does not exist; Ring A is selected from at least one R A Substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R A Selected from alkyl, halogen, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, -O-cycloalkyl; R 2 Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2b The substituent is selected from alkyl groups and halogens, and the R group is selected from alkyl groups and halogens. 2a and R 2b Independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups; R 3 Selected from hydrogen, halogens, and alkyl groups; R 4a R 4b Selected alone from alkyl, halogen, nitrile, alkoxy, haloalkyl, cycloalkyl, or, R 4a R 4b Together they cyclize into substituted or unsubstituted cycloalkyl or heterocycloalkyl groups, wherein the substitution is selected from alkyl, halogen, haloalkyl, or alkoxy groups; X 1 Selected from R X1 R X2 It is selected alone from alkyl, alkenyl, alkynyl, nitrile, alkylnitrile, haloalkyl, haloalkenyl, NT1T2, or substituted or unsubstituted -(CH2). c -NT1T2, or substituted or unsubstituted -(CH2). f -cycloalkyl, -(CH2) e -O-alkyl, alkylheteroalkyl, haloheteroalkyl, or substituted or unsubstituted aryl, heteroaryl, or substituted or unsubstituted cycloalkyl, heteroalkyl, wherein the substitution is selected from alkyl, cycloalkyl, alkoxy, halogen, wherein T1 and T2 are individually selected from alkyl, haloalkyl, cycloalkyl, heteroalkyl, or T1 and T2 together cyclized into substituted or unsubstituted heteroalkyl, wherein the substitution is selected from alkyl, halogen, wherein c, f, e are selected from 1, 2, 3, 4, 5 or 6; R 7 and R 8 Selected independently from hydrogen, alkyl, or R 7 and R 8 Together they cyclize into substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups, wherein the substitution is selected from alkyl, alkoxy, halogen, haloalkyl, or cycloalkyl groups, and at least one substitution is performed. R 9 Selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, and cycloalkyl; Where m1, m2 are 0, m3 is 2, W is N, and R 9 For hydrogen, R 7 and R 8 When they cyclize together to form cyclopropyl or cyclobutyl, R 2 Not for When ring A is selected from R A Replacement m1 and m2 are 0, m3 is 2, W is N, R 9 When it is methyl, R 7 and R 8 One of them is not hydrogen.
3. The compound according to claim 1, or its racemate, its isomer, or its pharmaceutically acceptable salt, characterized in that, When b is 1, X 2 R 4b For hydrogen, R 5 and R 6 Together they become a ring When Z is selected from N, it is selected from the structure shown in equation (III). Where m1, m2, and m3 are each selected from 0, 1, or 2; m is selected from 0, 1, 2, 3, or 4; and a is selected from 0 or 1. Y is selected from CH, N, O, and S. When Y is selected from O and S, R 1 It does not exist; W is selected from O, N, and S. When W is selected from O and S, R 9 It does not exist; Ring A is selected from at least one R A Substituted cycloalkyl, heterocycloalkyl, said R A Selected from alkyl, alkoxy, halogen, and haloalkyl; R 1 Selected from hydrogen, alkyl, alkoxy, halogen, and haloalkyl; R 2 Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2b The substituent is selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkenyl groups, and the R group is selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkenyl groups. 2a and R 2b Independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups; R 3 Selected from hydrogen, halogen, alkyl, and alkoxy groups; R 4a Selected from hydrogen, halogen, alkyl, alkoxy, and cycloalkyl; X 1 Selected from R X1 R X2 It is selected alone from alkyl, alkenyl, alkynyl, nitrile, alkylnitrile, halogen, haloalkyl, haloalkenyl, NT1T2, or substituted or unsubstituted -(CH2). c -N T1T2, or substituted or unsubstituted -(CH2). f -cycloalkyl, -(CH2) e -O-alkyl, -(CH2) p -O-cycloalkyl, -CT3T4-O-alkyl, or substituted or unsubstituted aryl, heteroaryl, or substituted or unsubstituted cycloalkyl, heterocycloalkyl, wherein the substitution is selected from alkyl, cycloalkyl, alkoxy, halogen, wherein T1, T2, T3, T4 are individually selected from hydrogen, halogen, nitrile, alkyl, haloalkyl, alkoxy, cycloalkyl, heterocycloalkyl, or T3 and T4 together cyclized into substituted or unsubstituted cycloalkyl, heterocycloalkyl, wherein the substitution is selected from alkyl, halogen, alkoxy, wherein c, f, p, e are selected from 1, 2, 3, 4, 5 or 6; R 7 and R 8 Selected independently from hydrogen, alkyl, haloalkyl, or R 7 and R 8 Together they cyclize into substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups, wherein the substitution is selected from alkyl, alkoxy, halogen, haloalkyl, or cycloalkyl groups, and at least one substitution is performed. R 9 Selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, and cycloalkyl; When Y is selected from O, ring A is selected from cyclopropyl or R 2 Selected from R 3 Selected from fluorine, R 4a Selected from methyl, X 1 Selected from R X1 Selected from ethyl, hour, Selected from 4. The compound according to claim 1, or its racemate, its isomer, or its pharmaceutically acceptable salt, characterized in that, When a is 0 and b is 1, X 1 for X 2 When Z is hydrogen and is selected from N, it is selected from the structure shown in formula (IV). Where m is 0, 1, 2, 3 or 4; Ring A is selected from at least one R A Substituted aryl and heteroaryl, said R A Selected from alkyl, halogen, alkoxy, cycloalkyl, haloalkyl, and haloalkoxy groups; R 2 Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2b The substituent is selected from alkyl, halogen, haloalkyl, and haloalkenyl groups, and the R group is selected from alkyl, halogen, haloalkyl, and haloalkenyl groups. 2a and R 2b Independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups; R 3 Selected from hydrogen, halogens, and alkyl groups; R 4a Selected from hydrogen, halogen, alkyl, cycloalkyl, and alkoxy groups; R X1 It is selected alone from alkyl, alkenyl, alkynyl, nitrile, haloalkyl, haloalkenyl, or substituted or unsubstituted -(CH2). e -O-alkyl, -(CH2) p -O-cycloalkyl, saturated or unsaturated C 5-12 Ring, C 5-12 Heterocyclic, wherein the substitution is selected from alkyl, halogen, alkoxy, or haloalkyl; R 5 and R 6 Selected alone from alkyl, alkoxy, cycloalkyl; or, R 5 and R 6 Together they cyclize into substituted or unsubstituted heterocyclic alkyl groups, wherein the substitution is selected from alkyl, alkoxy, nitrile, alkyl nitrile, halogen, cycloalkyl, alkylsulfonyl, alkoxycarbonyl, alkylamino, -(CH2). e -O-alkyl, haloalkyl, haloalkenyl, wherein the substitution is at least one, and e and p are individually selected from 1, 2, 3, 4, 5 or 6.
5. The compound according to claim 1, or its racemate, isomer, or pharmaceutically acceptable salt, characterized in that, When a is 0, b is 1, R 4b When hydrogen is used, the structure is selected from that shown in formula (V). Where m is 0, 1, 2, 3 or 4; Z is selected from C, CH, N; Ring A is selected from at least one R A Substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R A Selected from alkyl, halogen, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, -O-cycloalkyl; R 2 Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2b ), the R 2a and R 2b The substituents are independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and the substituted substituents are selected from alkyl, halogen, haloalkyl, and haloalkenyl. R 3 Selected from hydrogen, halogens, and alkyl groups; R 4a Selected from hydrogen, halogens, alkyl groups, and cycloalkyl groups; X 1 X 2 Selected independently from hydrogen, Or, X 1 X 2 Together they cyclize into substituted or unsubstituted heterocyclic alkyl or heteroaryl groups, wherein the substituted substituents are selected from alkyl groups and halogens; R X1 R X2 The substituent is selected from alkyl, alkenyl, alkynyl, nitrile, alkylnitrile, haloalkyl, haloalkenyl, or substituted or unsubstituted -alkyl-O-alkyl, -alkyl-O-cycloalkyl, -alkyl-NH-aryl, -alkyl-NH-heteroaryl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein the substituted substituent is selected from alkyl, halogen, alkoxy, haloalkyl; R 5 and R 6 It is selected independently from alkyl, alkoxy, cycloalkyl, -AEEA-AEEA-γE-CO-(CH2) t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, R 5 and R 6 At least one of them is selected from -AEEA-AEEA-γE-CO-(CH2). t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, wherein the substituent is selected from hydrogen, alkyl, halogen, haloalkyl, -NH2; Or, R 5 and R 6 Together they are cyclically formed by at least one R a Substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R a Selected from hydrogen, alkyl, alkoxy, halogen, cycloalkyl, -alkyl-O-alkyl, haloalkyl, -AEEA-AEEA-γE-CO-(CH2) t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, and at least one R a Selected from -AEEA-AEEA-γE-CO-(CH2) t -CO2H, substituted -(CH2) u -O-(CH2) v -O-alkyl, wherein the substituent is selected from hydrogen, alkyl, halogen, haloalkyl, -NH2, wherein u and v are individually selected from 1, 2, 3, 4, 5 or 6, and t is selected from positive integers from 8 to 20.
6. The compound according to claim 1, or its racemate, isomer, or pharmaceutically acceptable salt, characterized in that, When a is 0, b is 0, and Z is CH, the structure shown in equation (VI) is selected. Where m and n are each selected from 0, 1, 2, 3 or 4; Ring A is selected from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups; R A Selected from alkyl, halogen, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, -O-cycloalkyl; R 2 Selected from substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -CH(R) 2a (R) 2b ), the R 2a and R 2b The substituents are independently selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and the substituted substituents are selected from alkyl, halogen, haloalkyl, and haloalkenyl. R 3 Selected from hydrogen, halogens, and alkyl groups; R 4a R 4b Selected independently from hydrogen, halogen, alkyl, alkoxy, cycloalkyl, or R 4a R 4b Together they are cyclically converted into at least one R k Substituted cycloalkyl, heterocycloalkyl, said R k Selected from hydrogen, alkyl, halogen, and haloalkyl; X 1 X 2 Selected independently from hydrogen, Or, X 1 X 2 Together they cyclize into substituted or unsubstituted heterocyclic alkyl or heteroaryl groups, wherein the substituted substituents are selected from alkyl groups and halogens; R X1 R X2 The substituent is selected from alkyl, alkenyl, alkynyl, nitrile, alkylnitrile, haloalkyl, haloalkenyl, or substituted or unsubstituted -alkyl-O-alkyl, -alkyl-O-cycloalkyl, -alkyl-NH-aryl, -alkyl-NH-heteroaryl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein the substituted substituent is selected from alkyl, halogen, alkoxy, haloalkyl; R 5 and R 6 Together they are cyclically formed by at least one R a Substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, said R a The substituents are selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl, substituted cycloalkyl, substituted -alkyl-O-alkyl, substituted -alkyl-O-cycloalkyl, wherein the substituents are selected from hydrogen, alkyl, halogen, haloalkyl; Where, when m is 0 or 1, R 4a R 4b Neither of them are hydrogen, or R 4a R 4b Together they are cyclically converted into at least one R k Substituted cycloalkyl and heterocycloalkyl groups.
7. The compound according to any one of claims 1-6, or its racemate, isomer, or pharmaceutically acceptable salt, characterized in that, The alkyl group is selected from C. 1-6 alkyl group, the C 1-6 The alkyl group is selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, 1-ethylpropyl, 2-methylbutyl, tert-pentyl, 1,2-dimethylpropyl, isopentyl, neopentyl, n-hexyl, isohexyl, sec-hexyl, tert-hexyl, neohexyl, 2-methylpentyl, 1,2-dimethylbutyl, and 1-ethylbutyl. The alkoxy group is selected from C. 1-6 The alkoxy group, the C 1-6 The alkoxy group is selected from methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, sec-pentoxy, 1-ethylpropoxy, 2-methylbutoxy, tert-pentoxy, 1,2-dimethylpropoxy, isopentoxy, neopentoxy, n-hexyloxy, isohexyloxy, sec-hexyloxy, tert-hexyloxy, neohexyloxy, 2-methylpentoxy, 1,2-dimethylbutoxy, and 1-ethylbutoxy; the aryl group is selected from five- or six-membered aryl groups; the heteroaryl group refers to an aryl group in which at least one carbon atom is substituted by a heteroatom. The alkenyl group is selected from C. 2-6 alkenyl, C 2-6 The alkenyl group is selected from vinyl, 1-propenyl, 2-propenyl, 1-methylvinyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl 3-Methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl 2-Methyl-3-pentenyl, 3-Methyl-3-pentenyl, 4-Methyl-3-pentenyl, 1-Methyl-4-pentenyl, 2-Methyl-4-pentenyl, 3-Methyl-4-pentenyl, 4-Methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-1-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl alkenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-1-butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl and 1-ethyl-2-methyl-2-propenyl; The alkynyl group is selected from C. 2-6 The alkynyl group, the C 2-6 The alkynyl group is selected from ethynyl, propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 2-hexynyl, and 3-hexynyl. The alkyl nitrile is selected from acetonitrile, propionitrile, butyronitrile, isobutyronitrile, valerate, isovaleritrile, and hexanonitrile; The aryl group is selected from five-membered or six-membered aryl groups; the heteroaryl group refers to an aryl group in which at least one carbon atom is replaced by a heteroatom.
8. The compound according to any one of claims 1-6, or its racemate, isomer, or pharmaceutically acceptable salt, characterized in that, The cycloalkyl group is selected from C 3-12 Cycloalkyl groups, preferably the C 3-12 The cycloalkyl group is selected from C 3-8 cycloalkyl, the C 3-8 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The heterocycloalkyl group refers to a cycloalkyl group in which at least one carbon atom is replaced by a heteroatom. The alkyl heterocycloalkyl group refers to a heterocycloalkyl group in which at least one hydrogen atom is replaced by an alkyl group.
9. The compound according to any one of claims 1-6, or its racemate, isomer, or pharmaceutically acceptable salt, characterized in that, The halogen is selected from fluorine, chlorine, bromine, and iodine; a haloalkyl means that at least one hydrogen atom on an alkyl group is replaced by a halogen, and a haloheteroalkyl means that at least one hydrogen atom on a heterocyclic alkyl group is replaced by a halogen.
10. The compound according to any one of claims 1-6, or its racemate, isomer, or pharmaceutically acceptable salt, characterized in that, The heteroatom is selected from nitrogen, oxygen, and sulfur, and there is one or more heteroatoms.
11. The compound according to any one of claims 1-6, or its racemate, isomer, or pharmaceutically acceptable salt, characterized in that, a is 0 or 1, b is 0 or 1; m is 1 or 2; Y is O or N; Z is CH or N; Ring A is selected from cyclopropyl, cyclobutyl, ... By at least one R A The replaced A ring is selected from R 1 Selected from hydrogen and methyl; R 2 Selected from cyclohexyl, cycloheptyl, R 3 Selected from fluorine; R 4a R 4b Selected independently from hydrogen, methyl, or R 4a R 4b They cyclize together to form cyclopropyl and cyclobutyl groups; X 1 X 2 Selected independently from hydrogen, R X1 Selected from ethyl, R 5 and R 6 Together they formed a ring Further selection R 9 As defined above.
12. The compound according to claim 2, or its racemate, its isomer, or its pharmaceutically acceptable salt, characterized in that, m1 and m2 are 0, m3 is 2, m is 1, and W is N; The A ring is selected from: The at least one R A The replaced A ring is selected from R 2 Selected from cyclohexyl, cycloheptyl, R 3 Selected from fluorine; R 4a R 4b They cyclize together to form cyclopropyl and cyclobutyl groups; X 1 Selected from R X1 Selected from ethyl, R 7 Selected from hydrogen, R 8 Selected from methyl, or R 7 and R 8 They cyclize together to form cyclopropyl and cyclobutyl groups; R 9 It consists of hydrogen and methyl groups.
13. The compound according to claim 3, or its racemate, isomer, or pharmaceutically acceptable salt, characterized in that, m1 and m2 are selected from 0; m3 is selected from 2; m is selected from 1. Y is selected from N and O, and W is selected from N; A is selected from cyclopropyl, cyclobutyl, R 1 Selected from hydrogen and methyl; R 2 Selected from cycloheptayl, R 3 Selected from fluorine; R 4a Selected from methyl; Z is selected from R X1 Selected from ethyl, R 5 Selected alone from hydrogen, R 6 Selected from methyl, Or, R 5 and R 6 They cyclize together to form a cyclopropyl group.
14. The compound according to claim 4, or its racemate, isomer, or pharmaceutically acceptable salt thereof, characterized in that, m is 1; The A ring is selected from The at least one R A The replaced A ring is selected from R 2 Selected from R 3 Selected from fluorine; R 4a Selected from methyl; R X1 Selected from ethyl, R 5 and R 6 Together they formed a ring 15. The compound according to claim 5, or its racemate, isomer, or pharmaceutically acceptable salt, characterized in that, m is 1; and / or t is 16; And / or Z is N; And / or ring A is selected from By at least one R A The replaced A ring is selected from: and / or R 2 Selected from cycloheptayl, and / or R 3 Selected from fluorine; and / or R 4a Selected from methyl; and / or X 1 Selected from X 2 Selected from hydrogen, R X1 Selected from ethyl, and / or R 5 and R 6 Together they form a ring:
16. The compound according to claim 6, or its racemate, isomer, or pharmaceutically acceptable salt, characterized in that, m is 1 or 2; and / or n is 1; And / or ring A is selected from By at least one R A The replaced A ring is selected from: and / or R 2 Selected from and / or R 3 Selected from fluorine; and / or R 4a R 4b Selected independently from hydrogen, methyl, or R 4a R 4b They cyclize together to form a cyclopropyl group; and / or X 1 Selected from X 2 Selected from hydrogen, the R X1 Selected from ethyl, and / or R 5 R 6 Together they become a ring 17. The compound according to any one of claims 1-16, or its racemate, isomer, or pharmaceutically acceptable salt, characterized in that, The structures are selected from those shown in Tables 1 and 2.
18. A pharmaceutical composition, characterized in that, The compound comprising a therapeutically effective amount of any one of claims 1-17, or a racemic mixture thereof, an isomer thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier thereof.
19. The use of the compound of any one of claims 1-17, or a racemic mixture thereof, or an isomer thereof, or a pharmaceutically acceptable salt thereof, and the pharmaceutical composition of claim 18 in the preparation of a medicament for treating a disease, characterized in that, The diseases mentioned are IL-17A-related diseases, specifically psoriasis and arthritis.
